

# Index

Page numbers followed by 'f' indicate figures, 't' indicate tables, and 'b' indicate boxes.

## A

- Abducent nerve, 74
  - course of, 74, 76f
  - lesions of, 76b
- ABO blood groups, 141
- Acanthamoeba*, 462, 477–478, 498–499, 499f
  - host response to, 478
  - keratitis, 477–478, 477f
  - as 'Trojan horse', 478
  - virulence factors of, 478
- Accommodation, 30
  - ciliary muscles, 217–218, 312
  - lens zonules, 35
- Acetazolamide, 359.e2b
- Acetyl coenzyme A, 193
- Acetylcholine, 355
  - amacrine cells and, 267
  - cell depolarization and, 344–345
  - depolarization, 263
  - inhibition of, 356
  - parasympathomimetics and, 355–356
  - sympathetic system and, 357, 357f
  - tear fluid release and, 202.e1f
- Acetylcysteine, 355
- Achromatopsia, 308
- Acid burns, 487
- $\alpha_1$ -acid glycoproteins, 341
- Acinar cells, 200–201
- Actin, 226
  - dynamitin interaction, 173, 173f
  - stress fibre, 172, 189
- Actin-binding proteins, 172–173
- Actin-myosin motor, 388–389
- Actinomycetes, 494–495
- 'Action-perception cycle', 308
- 'Active pulley hypothesis', 62–63
- Acute-phase response, 394
- Acute retinal necrosis, 496
- ADAMTs (A disintegrin and metalloproteinase with thrombospondin motifs), 182
  - host response to injury, 383
- Adaptive optics, 280, 304, 305f
- Addressins, 418
- Adenoid cystic carcinoma, 537
- Adenosine monophosphate-activated protein kinase (AMPK), 190
- Adenyl cyclase, 345–346, 345f
- Adenylate cyclase, 225
- Adherens junctions, 189, 189t
- Adhesion molecules, 448
- Adnexa, 77–92
- Adnexal glands, benign tumours of, 523
- Adrenergic agonists, 225, 208.e1b, 359.e1
- $\beta_2$ -adrenergic agonists, 359.e1
- Adrenergic antagonists, 225, 359b, 359.e1
- Adrenergic neurotransmitters, 359f
- Adrenergic receptors, 208, 358b, 359f, 208.e1f
  - intraocular pressure control, 225, 358
  - profile of, 360t
- Advanced glycation end (AGE) products, 191, 192f
- Affinity chromatography, 145
- Ageing, 505, 506b
  - cataract associated with, 511–512
- $\alpha$ -agonists, 358
- $\beta$ -agonists, 358
- Aicardi syndrome, 138
- AIDS (acquired immunodeficiency syndrome)
  - cytomegalovirus retinitis and, 497
  - retinitis and, 403.e2
- Albinism, 155
  - enzyme defects in, 155f
- Albumin, drug binding, 341
- Aldose reductase pathway, 191, 191f, 235
  - cataract, 238
- Alkali burns, 487
- Alleles, 130, 139
  - linkage analysis of, 140
- Allergic eye disease, 445–447
  - treatment of, 361b
- Allergy, 445–450
  - disease production mechanism in, 448
- Amacrine cells, 43f, 47f, 49, 266–267
  - dopamine effect on, 267
  - ON/OFF microcircuitry, 291
  - retinal microcircuitry, 265–266, 292f, 295, 296f
- Amadori products, 191, 192f
- AMBEGUJAS phenomenon, 318–319, 320f
- Amino acid(s)
  - cataract, 511–512
  - metabolism disorders, 504–505
- Amino acid transporters, 243–244
- Aminoacyl-tRNA synthetases, 133–134
- $\gamma$ -aminobutyric acid (GABA), 265
  - amacrine cells and, 266–267
  - horizontal cells and, 48–49
- Amniotic cavity, 103.e2
- Amyloid, 507–508
- Anaphase, 131
- Anatomical terms of reference, 1, 2f
- Anergy, 442–443
- Aneuploidy, meiotic, 136.e1
- Angioid streaks, 506
- Aniridia, 127b
- Aniseikonia, 317
- Ankylosing spondylitis, 139
- Ankyrin-spectrin-actin, 172–173
- Anophthalmia, 112b
- Anterior chamber angle
  - development of, 127, 128f
  - fluid transport and, 215–216
  - malformation of, 127b
- Anterior chamber-associated immune deviation (ACAID), 457
- Anterior segment
  - antioxidation in, 220–221
  - detoxification in, 220–221
  - cytochrome P<sub>450</sub> system in, 220
- Antibodies, 396–399
  - diversity, 441b
  - engineering for therapeutic use, 400b, 400f
  - fragments, 399
  - generation during B-cell ontogeny, 439, 441f
  - genetic control of production, 439
  - H chains, 396–397
  - L chains, 396–397
  - production, 439
  - structure, 396, 397f, 397.e1f
- Anticholinergic drugs, 217–218
- Anticholinesterases, 356b
- Antigen(s)
  - binding, 427–432, 429f
  - endocytosis, 438
  - epitopes, 397
  - intracellular, 396
  - MHC, 424–426, 432
  - microbials, 439
  - presentation, 432–437
- Antigen presentation
  - active immune response, 435
  - B cells as, 438
  - cross-presentation, 421
  - HLA, 432
  - lipid, 433f
  - local, 396, 412
  - sugars, 432

- Antigen presenting cells (APCs), 395, 422f  
 antigen recognizable, 421–424  
 lymph nodes, 414–415  
 processing, 422–423, 424f  
 defects, 422  
 Antigen recognition, 395, 421–424  
 by B cells, 437–438  
 MHC molecule, 421  
 Antigen-antibody binding, 397–399  
 Antihistamines, 360–361  
 actions of, 361b  
 Antimuscarinic agents, 357t  
 Antioxidant systems, 220–221  
 Antioxidants, 360b  
 'Anti-saccadic task' test, 333  
 Anti-sense oligonucleotides, 147  
 Anti-TNF agents, 365–366, 366f  
 Anti-VEGF therapy, 353f  
 Apolipoprotein D, 199–200  
 Apoptosis, 146–147, 489–490, 491f  
 and death receptors, 167, 168f  
 detection of, 147  
 gene regulation of, 147b  
 signaling pathways, 168b  
 Apraclonidine hydrochloride, 359.e1  
 Aptamers, 352–353  
 AQP0 gene, 233  
 Aquaporin(s), 233  
 expression, 233f  
 Aquaporin-0, 229, 233, 233f  
 modification with age, 237  
 Aquaporin 1, aqueous humour transport, 207–208  
 Aquaporin water channels, 224  
 Aqueous deficiency, 354  
 Aqueous humour, 218  
 blood-aqueous barrier, 218–220  
 circadian regulation of, 225  
 composition of, 222–223  
 dynamics, 222–228  
 episcleral circulation of, 227–228  
 functions of, 36–37  
 glucose, 235  
 hydrogen peroxide, 221  
 production of, 30–31, 31f  
 secretion of, 222–223, 224b, 224f  
 and adrenergic receptors, adenylate cyclase with, 225  
 and M<sub>3</sub> muscarinic receptors, 223–225  
 neural/autonomic control of, 223–225  
 and nucleotide receptors, 225  
 and nucleotides, 225  
 uveoscleral drainage of, 227  
 Aqueous outflow pathways, 24–26, 225–228  
 ciliary muscle action on, 30  
 control of, at trabecular meshwork, 226  
 'conventional', 24  
 development of, 127  
 and juxtacanalicular cribriform meshwork, 226  
 'non-conventional', 24–26  
 Arachidonate, 197, 197b, 197f  
 Arachnoid granulations, 12  
 Arachnoid mater, 12, 9.e1f  
 Arachnoid villi, 12  
 Arcuate eminence, 10t  
 Arcus senilis, 506  
 ARP 2/3 complex, 172f, 173  
 Arrestin, 261, 264f, 430, 430f  
 Arteriovenous fistulas, in cavernous sinus, 13b  
*Ascaris* spp., 499  
 Aspartate, and disc shedding, 247, 248f  
*Aspergillus* spp., inflammatory disease, 497  
 Aspirin, 239–240, 362–363  
 Asthma, 445–447  
 Astigmatism, 15b, 15f, 209  
 Astrocytes, in retina, 49, 50f  
 Astrocytic hamartoma, 531, 532f  
 Atopy, 445–447  
 Atrial natriuretic peptide (ANP), 225  
 Atrophy, 490  
 Aubert's phenomenon, 311, 311b, 311f  
 Autoantigens, 444  
 Autoimmune disease, 394  
 dysregulated, 488  
 inflammatory, 500–504  
 Autoimmune regulator (AIRE) gene, 413–414  
 Autoimmunity, 439–445  
 Autonomic nervous system, ocular drugs and, 355–358  
 Autosomal dominant disorders, 137.e1, 137.e1f  
 ocular disease, 152t  
 Autosomal recessive disorders, 137.e1, 137.e1f  
 ocular disease, 152t  
 Autosomes  
 dominant, 137  
 recessive, 137, 137.e1, 137.e1f  
 Avellino dystrophy, 517  
 Axenfeld-Rieger's anomaly, 120b, 127b  
 Azathioprine, 347b, 364b
- B**
- B cell(s), 380–381  
 activation, 437–439  
 affinity maturation, 439  
 anergy, 443–444  
 antibody production, 439  
 differentiation, 438–439  
 in effector response, 396  
 immune response, 380–381  
 isotype switching in, 448  
 maturation, 438f  
 memory, 420  
 ontogeny, 439, 441f  
 polyclonal response in, 439  
 somatic mutations, 439  
 tolerance, 443–444  
 B cell lymphoma, 535  
 B7:CD28 interaction, 435  
 Bacteria  
 opsonization of, 492–493  
 toxins, 487–488  
 Bacterial infection(s), 473–475  
 chronic, 494–495  
 endophthalmitis, 459, 474–475  
 inflammatory disease, 494–495  
 ocular surface in, 473–474  
*Bartonella* spp., 494–495  
 Basal cell carcinoma, 523  
 infiltrating/sclerosing subtype, 523, 524f  
 micronodular subtype, 523  
 nodular/solid, 523, 524f  
 superficial, 523  
 Basal cells, proliferation of, 211  
 Basal lamina, 15–16  
 Basement membrane  
 endothelial cell binding, 189, 189t  
 epithelial cell binding, 189, 189t  
 structure of, 183–184, 185f  
 Basic fibroblast growth factor (bFGF), 244–245  
 Basophilic cytoplasm, 89–91  
 Basophils, 376f, 378–379  
 BAX gene, 147b  
 Bcl-2 gene, 147b  
 Behçet's disease, 425, 500  
 Benign mixed tumour, 536–537, 536f  
 Benzalkonium chloride, 354  
 Bergmeister's papilla, 118–119  
 Best disease, 515, 516f  
 Bestrophins  
 and aqueous humour, 228  
 and ion transport, in RPE, 255  
 Betaxolol, 360b  
 Bezold-Brücke phenomenon, 272–273  
 Binocular single vision (BSV) field, 314, 315b, 315f–316f  
 driving licence requirement, 316f  
 Binocular viewing, perception, 287  
 Binocular vision, 309–313  
 Biochemical pathways, ocular function effects, 189–198  
 Biologics, 365–366  
 Bipolar cells, 43f, 45–46, 47f, 263–265, 266f  
 blue cone-specific, 46  
 colour opponency, 306  
 colour perception, 306  
 midget, 46, 280–282  
 retinal light stimulus detection, 291  
 retinal microcircuitry, 265–266, 291, 293f, 295f  
 Blastocyst, 103.e2  
 'Blind spot' phenomenon, 59–61

- Blindness  
  chlamydial infection, 497  
  from optic nerve lesion, 99f  
  'Blindsight', 332  
  Blink rate, 198  
  Blink reflex, 80, 82t, 198, 202  
  Blinking, 463  
  Bloch's law, 278–279  
   $\beta$ -blockers, 358  
    actions on IOP, 360b  
    topical, 360b  
  Blood, inflammatory reactions of, 500  
  Blood-aqueous barrier, 218–220  
    drug distribution limitation by, 342, 352  
    iris blood vessels, 216–217  
  Blood-ocular barrier, 28  
  Blood-retinal barrier, 52, 245  
    drug distribution limitation by, 342, 352  
  Blue cone monochromacy, 150–151  
  'Blue' sclera, 22b  
  Bone marrow  
    lymphomyeloid cell maturation, 402  
    stem cells, 413  
  Bones, membranous, 129.e1  
  *Borrelia burgdorferi*, 494–495  
  Bowman's layer, 16, 16f, 203f  
    adhesion to basement membrane, 211  
    collagen, 204  
    corneal dystrophies of, 516  
    corneal epithelium integrity, 203  
  Bowman's membrane, 464  
    development of, 119–120  
    drug administration in, 348  
  Bradykinin system, 492–493  
  Brain, processes involved, 270.e1f  
  Brain natriuretic peptide (BNP), 225  
  Brainstem, 329, 334–335  
    lesions, 331, 333b  
  Brevican, 215  
  Brimonidine, 359.e1  
  Bronchus-associated lymphoid tissue (BALT), 416  
  Bruch's membrane, 41, 42f, 55, 56f–57f  
    composition, 255–256  
    elastic fibre degeneration, 506  
    morphogenesis, 114  
  Bulbar fascia, 62  
  Bullous pemphigoid antigen 180, 182  
  Buphthalmos, 21b  
  Bystander activation, 444
- C**  
  C-type lectins, 467, 469f  
   $\text{Ca}^{2+}/\text{Mg}^{2+}$ ATPase, 208–209, 235  
  Cadherins, 189  
  Caffeine, 239  
  Calcium  
    in cellular activity mediation, 345–346  
    intracellular concentration of, 345–346  
    Calcium-calmodulin complex, 345–346, 346f  
  Calcium ions  
    intracellular concentration, 259–261  
    mobilization, 261  
  Calgranulin, 455–456  
  Calpactins, 236  
  Calpains, 227, 236  
  Canal of Schlemm, 24, 25f  
  *Candida*, 459  
    inflammatory disease, 497  
  *Candida albicans*, 475  
  Candidate gene analysis, 150  
  Canthus, 82  
  Capsulopupillary vessels, 121–123, 123f  
  Carbohydrate metabolism in lens, 235  
  Carbonic anhydrase, 359.e2b  
    type II, 224  
  Carbonic anhydrase inhibitors, 353–354  
  Carcinogenesis, 519–521  
  Carotid artery, internal, aneurysm in, 99f  
  Carteolol, 360b  
  Caruncula lacrimalis, 85–86  
  Caspase enzyme activation, 146–147  
  Cataract(s), 35b, 511–512  
    ageing associated, 511–512  
    formation of  
      age-related, 238–240, 239f  
      from chaperone function, failure of, 240  
      and insult to lens, 238  
    myotonic dystrophy and, 155–156  
    reduced vision in, 237–238  
    secondary, 512  
    from steroid oculotoxicity, 369  
    types, 238  
  Cavernous sinuses, 10, 11f–12f  
    arteriovenous fistulas in, 13b  
    cranial nerve lesions in, 71b, 76b  
    thrombosis in, 13b  
  Cavum trigeminale, 12, 12.e1  
  CCN (CYR61/CTGF/NOV) proteins, 184f, 185  
  CD1, 432  
  CD4<sup>+</sup> CD25<sup>+</sup> T regulatory cells, 421  
  CD4<sup>+</sup> T cells, 380  
    activation, 435  
    scleritis, 456  
  CD8<sup>+</sup> T cells, 412  
    scleritis, 456  
  CD31, 387  
  CD36, 214–215, 246, 255, 261–262  
  CD40-CD40L interactions, 435  
  CD40:CD40 ligand, 435  
  CD44, 435  
  Cell(s)  
    endoplasmic reticulum and Golgi apparatus, 164  
    intermediate filaments, 173–174, 175f–176f  
    intracellular matrix, 168b, 169–177  
    microfilaments, 165b, 169–173, 173t  
    mitochondria, 164–169, 167f  
    nucleolus, 169  
    nucleus, 169  
    plasma membrane, 161–164, 162f  
    structure of, 160–161, 161f  
  Cell adhesion, 186–188  
    and transmembrane signaling, 188  
  Cell adhesion molecules (CAMs), 386  
    integrin, 386  
  Cell adhesion proteins, 189  
  Cell biology, 146–150  
  Cell cycle, 131f  
    control of, 132b, 132f  
  Cell damage, agents and conditions  
    causing, 486–489  
  Cell death, mechanism of, 489–490  
  Cell destiny, control of, 146–150  
  Cell division, 130–132, 135–136  
  Cell-mediated immunity, 411  
  Cell membrane, proteins, glycation of, 191–193  
  Cell signalling, immunological synapse, 423–424  
  Cellcept, 364b  
  Cellular retinal binding protein (CRALBP), 258–259  
  Cellular retinol-binding protein (CRBP), 257  
  Central retinal artery occlusion, 510–511  
  Central retinal vein occlusion, 511, 512b  
  Central vitreous, 38  
  Centriole, 177  
  Cerebellum, 334–336  
  Ceroid/lipofuscin, 237  
  Ceruloplasmin, 253  
  Cervico-ocular reflex, 329  
  Chalazion, 83b, 500, 500f  
  Chamber angle, malformation of, 127b  
  Chandler syndrome, 518  
  Chaperone proteins, 159.e2, 159.e2f  
    failure of, and cataracts, 240  
  CHARGE syndrome, 108b  
  *CHD7* gene, 108b  
  Chediak-Higashi syndrome, 155  
  Chemical agents, ocular tissue damage, 487  
  Chemoattractants, 387–388  
  Chemokine receptors, 404, 406f  
  Chemokines, 404, 406f  
    leucocyte activation by, 386  
    nomenclature for, 405t  
  *Chlamydia*, 372, 454, 455f, 497  
  *Chlamydia trachomatis*, 462–463  
    blindness and, 497  
  Chlorbutol, 354  
  Chloride pump, corneal, 208  
  Chlorine channel,  $\text{Ca}^{2+}$  dependent, 255  
  Chloroquine, retinopathy from, 368  
  Cholesterol, 194–195, 197f  
    lens fiber cell content, 233, 237f  
    retinal pigment epithelium, 255

- Cholinergic receptors, in corneal epithelium, 208.e1, 208.e1f
- Chondroitin sulphate, 226  
corneal, 187b, 205  
vitreous, 240–241
- Chondroitin sulphate proteoglycans, 21
- Choriocapillaris, 55–56, 56f–57f, 221  
development of, 124
- Chorioretinopathy, birdshot, 139
- Choristomas, 522
- Choroid, 55–59, 56f–57f  
ageing changes in, 58b  
angioma, 528f  
biochemical process, 221–222  
blood flow in, 221  
dendritic cells in, 59f  
development of, 124  
embryology, 108–110  
functions of, 221–222  
infarctions in, 59b  
lymphoid function, 222  
macrophages in, 59f  
mast cells in, 58f  
melanoma, 526  
neovascularization, 514b  
nerve supply of, 58–59  
non-vascular, 222  
as paracrine tissue, 215  
pigmentation of, 56  
 $P_{O_2}$  and  $P_{CO_2}$  and, 222  
stroma of, 56  
trauma response, 492  
vascular, 56, 56f–57f, 221–222  
venous blood in, 219f, 222
- Choroidal fissure, 106–108  
closure, 111
- Choroideraemia, 153–154
- Chromatic aberrations, 282
- Chromaticity, 272–273, 272f
- Chromatids, 131
- Chromatin, 157–158, 169
- Chromophore, 259  
cone, regeneration of, 257, 257f  
and opsin, 258–259, 260f–261f
- Chromosomal abnormalities, 488
- Chromosomal anomalies, 129.e4
- Chromosomes, 130  
crossing over of, 140  
cytogenetic analysis of, 130  
defects and gene mutations in, 135–137  
deletion of, 136, 137b  
division of, 135–136  
insertions in, 137b  
inversion in, 136  
meiosis, 131–132  
mitochondrial, 138, 167–169  
mitosis, 130–131, 131b  
numeric abnormalities in, 136.e1  
structural abnormalities in, 136–137  
translocation, 136
- Chronic progressive external ophthalmoplegia (CPEO), 490b
- Cicatricial conjunctival disease, 354
- Cicatriziation, conjunctival, 454–455
- Ciclosporin, 364b, 437
- Cidofovir, 352.e1b
- Ciliary arteries, posterior, 124
- Ciliary body, 30–32, 31f  
accommodation in, 30  
antioxidant systems, 220–221  
biochemical processes, 217–221  
blood-aqueous barrier, 219f  
breakdown of, 218–220  
blood flow in, 217, 217f  
blood supply of, 32  
coloboma, 108b  
cytochrome  $P_{450}$  system in, 220  
development of, 124–126, 125f  
eicosanoids, 220  
epithelial cells, non-pigmented, 31, 216  
epithelium, 124–125  
aqueous humour secretion, 222–223  
functions of, 217  
hydrogen peroxide, 221  
melanoma, 526  
nerve supply of, 32  
parasympathetic innervation of, 32  
pars plana in, 30  
pars plicata in, 30  
sensory innervation of, 32  
sympathetic innervation of, 32
- Ciliary folds, 117, 124–125
- Ciliary muscle, 30  
accommodation, 217–218, 218f, 312  
on aqueous outflow, 30  
arrangement of, 32f  
development of, 126  
parasympathetic antagonists, 356–357
- Ciliary nerves, 58–59
- Ciliary processes, 30, 31f
- Ciliary zone, 26
- Ciliopathies, 154b
- Cilioretinal artery, 52–53
- Cimetidine, 361
- Circadian rhythms  
entrainment, 296  
melatonin, 247, 276–277
- 11-cis retinal, 275–276, 275f
- Citric acid cycle, 209  
in lens, 235
- Clathrin-coated vesicles, 165, 165f
- Clinoid processes, posterior, 9
- Clonal deletion, 442
- Cloning, 142, 142f
- Cloquet's canal, 123–124
- Clotting cascade, 492–493
- 'Clump cells,' in iris stroma, 27f, 28
- Cluster of differentiation (CD), 381b
- Clusterin, 201–202
- Coat's disease, 532f
- Cocaine, 359.e1
- Codon deletions and insertion, 137b
- Cofilin, 189
- Colchicine, 174
- Collagen, 180–182, 180f  
in cornea, 16–18  
corneal, 182  
transparency, 204–205
- Descemet's membrane, 182
- fibrils, arrangement of, 204, 212–213, 214f
- glycation, 191–193, 192f
- iris, 182
- lens, 182
- retinal pigment epithelium, 117–118
- scleral, 21, 22f, 205, 205f
- triple helix of, 178–180, 179b, 179f, 181f
- types of, 180t
- vitreous, 182
- Collagen shields, 350–351
- Collagenous lamellae, 16–18
- Collarette, 26
- Collectins, 405  
activation of complement, 408  
innate immunity, 407b, 407f
- 'Collector units', 319
- Colliculus, 333
- Coloboma, 108b, 108f, 119b  
axial, 119b  
enucleation for malignant melanoma, 526
- Colorimetry, 302
- Colour  
constancy, 306–307, 318–319, 322  
discrimination, 302  
hues, 272  
discrimination, 303  
luminosity, 302–303  
perception, 324–325  
primary, 272  
processing, 318–319  
sensing, 271–273
- Colour blindness, 307–308  
red-green, 150–151
- Colour detection, 292, 294f  
photoreceptor, 303–305
- Colour matching tests, 306.e1, 306.e1f
- Colour-opponent mechanism, 306
- Colour vision, 271, 302–308  
trichromatic theory, 303
- 'Colouredness', 272–273
- Common tendinous ring, 5–6
- Complement, 405–410, 492–493  
activated, 387–388  
activation, 405  
regulation, 408–409, 409b, 409t  
cascade, 406–407, 408f  
effects, 405–406  
innate immunity, 407b, 407f  
ocular microbial barrier, 463  
receptors for, 409t  
tears, 463

- Complement pathway, 405–406
  - alternative, 408
- Complementarity-determining region (CDR), 396–397, 429, 429f
  - antigen binding sites, 439
  - somatic mutations occur, 439
- Complementary DNA (cDNA), 146
- Cone(s), 44f, 45
  - bipolar cells, 46, 262–263, 292, 293f
  - colour discrimination, 293
  - colour sensing, 271
  - discriminatory capacity, 280
  - foveal, 280–282, 285
    - blue-sensitive, 305
  - horizontal cell feedback, 292f, 294–295
  - light sensing, 307f
  - microcircuits, 291–292, 293f
  - monochromatism, 307
  - opsins, 304–305
  - pedicles, 44f, 45
  - photopigments, 305
  - psychophysical evidence for, 303–304
  - regeneration of, 257, 257f
  - resolving power of eye, 282
  - retinal light stimulus detection, 291
  - thresholds, 303
  - types, 303
- Congenital hereditary endothelial dystrophy, 518
- Congenital malformations, 129.e4
  - anterior chamber angle, 127b
  - corneal, 120b, 127b
  - glaucoma, 127b
  - hyaloid system, 124b
  - lens, 121b
  - nasolacrimal duct, 129.e6b
  - neural tube, 112b
  - optic nerve head, 119b
  - optic vesicle, 112b
  - periods of vulnerability, 129.e4
  - vitreous system, 124b
- Conjunctiva, 83–89, 84f–87f
  - allergic responses in, 85b
  - biochemical processes, 201–202
  - bulbar, 83f, 85–86, 86f–87f
  - cicatricial disease of, 354
  - cicatrizing disease of, 454–455
  - cysts, 537
  - dendritic cells, 86f–87f, 88, 453
  - drug administration in, 347–348
  - epithelium, 201–202
    - mucin production, 200–201
  - forniceal, 84f–85f, 85
  - glands in, 88–89
  - goblet cells, 86f–87f, 88, 200–201
  - keratin, 202
  - lymphocytes in, 88
  - lymphoid layer, 202
  - malignant melanoma, 525
  - mast cells, 359–361
  - melanocytes in, 86f–87f, 88
  - palpebral, 84f–85f, 85, 88
  - papillomas, 519–520
  - stroma, 202
  - structure of, 86–88
  - systemic disease in, 86b
- Conjunctiva-associated lymphoid tissue (CALT), 88, 202, 416
- Conjunctival sac, 83–85
  - drug administration in, 347–348
  - drug residence time in, 349–350
- Conjunctivitis, allergic, 445–446, 454f
- Connective tissue-activating peptides, 394
- Connexin, 229
- Consanguinity, 137.e1
- Contact lenses, 469–471
  - associated to fungal keratitis, 475
  - related corneal inflammation, 474
  - soft, 351
  - types, 210–211
  - wearing, 210–211, 210f
- Contraction furrows, of iris, 26
- Contrast sensitivity, 283–285, 284f
- Convergence, 305–307, 312, 327
- Cornea, 14–20, 198
  - ageing changes to, 20b
  - Aspergillus* and *Fusarium* in, 462
  - biochemical processes of, 203–215
  - calcification of, 507
  - cell turnover and wound healing in, 211–215, 211.e1f
  - limbal corneal stem cells in, 211–212, 212f
  - chloride pump, 208
  - collagen, 204–205
    - anchoring fibrils, 205, 205f
    - fibres in, 16–18
    - turnover, 207
    - type V, 204–205, 204f
  - combined granular-lattice dystrophy, 517
  - components of, 203
  - contact lens wearing, 210–211, 210f
  - crystallins in, 207
  - curvature, 209
  - dendritic cells, 207, 453, 464, 465f
  - development of, 119–120, 120f
  - drug administration in, 348
  - endothelial cell pump in, 207, 208b, 208f
  - endothelium, 19–20, 20f
    - development of, 119–120
    - transparency, 207–208
    - wound healing, 213
  - epithelium, 14–16, 16f, 203f
    - adhesion to basement membrane, 211
    - cell migration, 211
    - transparency, 203–204
    - wound healing, 211, 211.e1
  - fluid transport, 186f, 203–204
  - glucose utilization, 209
  - glycosaminoglycans, 16–18, 186, 187b, 205–206
  - granular dystrophy, 517, 517f
  - hysteresis of, 207
  - image formation, 209
  - iontophoresis of drugs in, 352
  - keratan sulphate, 186
  - keratocytes, 207
  - lattice dystrophy, 516
  - leucocytes, 207
  - leucoma, 120b
  - macrophages, 19f, 464, 465f
  - malformation of, 120b
  - and mucin, 200–201
  - mucous layer, 198f, 200–201
  - nerve supply of, 20, 21b
  - neurotransmitters in, 210
  - oedema of, 517
  - opacification of, 517
  - oxidative metabolism of, 209
  - oxygen handling by, 209–210
  - proteoglycans, 186
    - binding maps of, 206, 206f
    - and collagen fibrils, 205–206
    - linkage sites of, 205
    - organization of, 206, 206f
  - pyogenic infection of, 494
  - refractive surgery, 213
  - shape of, 14
  - stroma of, 16–18, 18f
    - wound healing, 212–213, 214f
  - structure of, 14–20, 16f
  - swelling pressure, 206–207
  - transparency of, 14, 203–209
    - surgical wounds to, 213
  - vascularization, 214–215
  - vitamin A, 215
  - in vivo confocal microscopy of, 15–16, 17f
- Corneal dystrophies, 515–518
- Corneal grafting, 457–459, 458f, 451.e1
- Corneal opacity, 491–492
- Corneal transplantation, 451
- Corneal ulcers
  - melting, 455–456
  - spontaneous central, 501
- Corneoscleral envelope, 14f
- Corneoscleral meshwork, 24, 25f
- Corrugator supercilii, 80–81, 81f
- Cortical activity, neuronal 'noise', 322
- Cortical centres, complex eye movement regulation, 333–334
- 'Cortical magnification factor', 285, 285f
- Cortical processing defect, 307–308
- Cortical vitreous, 37f, 38
- Corticosteroids, 364b, 477
- Cranial cavity, 1
  - osteology of, 7–13, 9f, 7.e2f
- Cranial fossa
  - anterior, 7–8
  - middle, 9, 9f
  - features on floor of, 10t
  - posterior, 7.e2

- Cranial nerves, 68–77  
 III, 69–71, 73f  
 IV, 71–74, 75f  
 V, 74–77, 78f  
 VI, 74, 76f  
 VII, 77  
 components of, functional analysis of, 68.e1t  
 origin of, 72f  
 sensory neurones, 129.e1
- Craniofacial abnormalities, 129.e5b
- Cranium, 1
- C-reactive protein, 395
- Cribiform meshwork, 24, 25f  
 development of, 127, 128f
- Critical flicker fusion, 271
- Critical fusion frequency, 301
- Crystallins, 121, 123f, 230–232, 230.e1b  
 cataract formation, 237  
 enzyme activities of, 235–236  
 glycation of, 237  
 heat-shock protein, model for, 230–231, 231f  
 homology of, with other enzymes, 230–231  
 micelle, 230–231  
 phosphorylation of, 231  
 structure of, 232f, 230.e1f
- Cuneus gyrus, 95
- Curuncula lacrimalis, 82
- CXC chemokines, 468b
- Cyanate, and cataract, 239–240
- Cyclic adenosine monophosphate (cAMP), 177  
 in drug-receptor interactions, 345  
 in intraocular pressure control, 225, 358  
 retinal neurotransmission, 258
- Cyclic guanosine monophosphate (cGMP)  
 neurotransmitter, 265–266, 267f  
 phototransduction, 259
- Cyclin-dependent kinases (CDK), 132b
- Cyclo-oxygenase 2 (COX-2), specificity of, 363
- 'Cyclopean' eye, 312–313, 313f, 317
- Cyclophosphamide, 364
- Cyclopia, 112b
- Cycloplegic refraction, antimuscarinic agents, 356–357
- CYP1B1 gene, 227, 347
- CYP2D6 enzyme, 220
- Cyst, 537–538  
 dermoid, 500, 537
- Cystic fibrosis, 147b, 137.e1
- Cystic fibrosis transmembrane conductance regulator (CFTR)  
 gene, 147b, 207
- Cystinosis, 505
- Cytidine triphosphate, 247
- Cytochrome C, 167–168
- Cytochrome P<sub>450</sub> system, 220, 342  
 and drug detoxification, 220, 221b, 221f
- Cytokine(s), 380  
 acute phase response, 394  
 adaptive immune responses, 399–404  
 inflammation, 403  
 innate immune responses, 399–404  
 Jak-STAT pathway, 404f  
 lymphomyeloid cell maturation, 402  
 networks, 403f  
 properties, 399–400, 401f  
 in specific immune reactions, 401–402
- Cytokine receptor(s), 402–403, 403f  
 antagonists, 402–403
- Cytolysis, 408
- Cytomegalovirus (CMV) retinitis, 472–473, 497, 497f  
 treatment of, 352.e1b
- Cytoplasm, 169
- Cytoskeletal fibres, group 3, 174–177
- Cytotoxic agents, 364
- Cytotoxic T cells, 396, 412  
 activation of, 435
- D**
- Dalen-Fuchs nodules, 502
- Damage-associated molecular patterns (DAMPs), 371
- Dark adaptation, 257, 273–279  
 curve, 274–277, 274b, 274f
- Dark currents, 262–263, 288, 288b, 288f  
 ATPase dependent, 243
- Death receptors, 167, 168f
- Decorin, 205
- β-defensins, ocular infection barrier, 463
- Degeneration, 505–514  
 composition/type of, 505–507  
 elastic fibre, 506  
 fatty, 506, 506f
- Degenerative vascular disease, 508–511
- Delayed-type hypersensitivity, 411
- Deletion, 136  
 failure, 444
- Dendritic cell (DC), 207, 371, 375f, 416–418  
 choroidal, 59f  
 conjunctiva, 86f–87f, 88, 453, 453f  
 conjunctival epithelial, 202  
 cornea, 453, 464, 465f  
 immature, 421f  
 from myeloid and lymphoid precursors, 378b, 378f  
 subsets, 378.e1b  
 surveillance function, 378.e1b
- Depolarization, 263, 265, 287, 344–345
- Depressor supercilii, 77–80
- Depth perception, 273, 312–317, 314f  
 motion detection/texture analysis, 319–320, 320f
- Dermatan sulphate, 21, 207, 226
- Dermoid, 522  
 cysts, 500, 537
- Descemet's membrane, 16f, 18–19, 20f  
 collagens, 182, 204  
 congenital hereditary endothelial dystrophy, 518  
 development of, 119–120
- Desmin, 174
- Desmocollin, 203–204
- Desmoglein, 203–204
- Desmosomes, 14–15, 174, 189, 189t, 172.e1, 172.e1f  
 spot, 203–204
- Diabetes, 504
- Diabetes mellitus, 191  
 cataract, 238  
 retinal blood flow, 246
- Diacylglycerol (DAG), 261
- Diakinesis, 131
- Diaphragma sella, 9, 11f–12f, 12, 12.e1
- Dichlorphenamide, 353–354
- Dichromatism, 308
- Diclofenac, 362–363
- Diencephalon, 103
- Diffraction, 282
- Dilator pupillae muscles, 26, 28, 126
- Diplopia  
 divergent squint, 313  
 heteronymous, 312–313
- Diplotene, 131
- Direct reverse signalling, 189
- Discoidin domain receptors (DDR), 182
- Discrimination, contrast sensitivity, 284–285
- Discriminatory capacity, 280
- Disease associations, 139  
 HLA-linked, 139t
- DNA, 132–135  
 fragment, 142  
 ordering of, 135
- DNA laddering, 147
- DNA ligase, 142
- DNA polymorphisms, 143
- DNA probe, 142
- Docosahexanate phospholipids, 247
- Docosahexanoic acid, 257
- Doll's head movements, 330
- Donder's law, 335
- Dopamine, 265, 267–268  
 receptors of, 208  
 and regulation of shedding, 247, 248f
- Dorsum sellae, 9
- Dorzolamide, 359.e2b
- Dose-response curve, 344.e1b
- Dot-blot hybridization, 146
- Double-stranded DNA (dsDNA), 132–133
- Dowling-Rushton equation, 275
- Down syndrome (trisomy 21), 136.e1, 129.e6b, 136.e1f
- DR4 associations, 139



- Drug(s)  
 absorption of, 340, 347  
   ocular, 347  
   topical, 348, 348b  
 acetylation of, 346–347  
 active transport of, 340  
 administration route of, 341, 341b, 347–348  
 agonist, 344b, 344.e1b, 344.e1f  
 antagonist, 344b, 344.e1b, 344.e1f  
 autonomic nervous system and, 355–358  
 biliary excretion of, 343–344  
 bioavailability of, 339  
 on cell activation, 437  
 clearance of, 342–343  
 conjugation, 342  
 contralateral eye effect, 354  
 delivery to eye, 347–348  
   advanced systems, 351–352  
   vehicles, 350b  
 diffusion of, 340  
 distribution of, 341–342, 341b  
 dose-response curve of, 344.e1b  
 efficacy of, 344.e1b  
 excretion of, 343–344  
 first-order kinetics of, 339, 340f  
 glomerular filtration of, 343  
 half-life of, 338–339  
 immunosuppressant, 364–366  
 immunosuppressive, 437  
 inactivation of, 349–350  
 interactions, 341  
 intracameral administration of, 352–353  
 intravitreal administration of, 352–353  
 ligand, 344b  
 lipid solubility of, 340–341  
 liposomes, 351–352  
 metabolism of, 342–343, 342b, 344f  
   in eye, enzymes involved in, 349b  
 as microsomal enzyme manipulators, 343b  
 ocular absorption of, 347  
 ocular iontophoresis, 352  
 oculotoxic, 369  
 oxidation of, 342  
 partial agonist, 344b  
 particulates, 351  
 pH of, 348–349  
 plasma concentration-time curve of, 338–339  
 potency of, 344.e1b  
 preservatives, 354  
 properties of, 340–341  
 protein-bound, 341  
 reabsorption of, 343  
 receptors, 344b  
   interactions, 344–347  
 renal excretion of, 343  
 secretion of, 343  
 semisolids (ointments), 350  
 slow-release preparations of, 350–351  
 solutions, 350  
 steady-state plasma concentration of, 339  
 systemic administration of, 353–354  
   ocular toxicity from, 368–369  
 tolerance, 344.e1b  
 topical medications, 354  
 vehicles for, 350–351, 350b  
 volume of distribution of, 339, 339f  
 zero-order kinetics of, 339, 340f
- Drug distribution limitation, 342  
 Dura mater, 9–12, 11f–12f  
 Dural folds, 9–10, 11f–12f  
 Dural venous sinuses, 10, 11f–12f, 9.e1f  
 Dysthyroid eye disease, 456  
 Dystrophies, 514–518  
 Dystrophin, 189, 264–265, 266f
- E**  
 E selectin, 448  
 Ectopis lentis, in Marfan syndrome, 35b  
 Ectropion, 83b  
 Edrophonium, 356b  
 EDTA, 354  
 Edwards syndrome (trisomy 18), 136.e1  
 Eicosanoid metabolite 12(R) HETE, 208–209  
 Eicosanoids  
   biological actions of, 362b  
   ciliary body, 220  
   iris, 220  
   ocular function effects of, 361–363  
   and retinal blood flow, 246  
   synthesis of, 362f  
 Elastic fibre degeneration, 506  
 Elastin, 182–183, 183f  
   degradation of, 183  
 Electro-oculogram, 298, 298b, 298f  
 Electroretinogram (ERG), 298–299, 299f  
   flicker, 302  
 Ellipsoid, 41–45  
 Elongation of very long fatty acids-like 1 (ELOVL1), 252  
 Embolism, 511b  
 Embryoblast, 103.e2  
 Embryology, 103, 104f–105f, 113f, 103.e1f  
 Embryonic stem cells, 148  
 Embryotoxon, 120b  
   posterior, 127b  
 Encephalo-trigeminal angiomatosis, 521  
 Endocrine exophthalmos, 500, 504, 505f  
 Endocytosis, 165b, 165f  
   in lens, 234  
 Endogenous materials, reactions to, 500, 500f  
 Endophthalmitis  
   bacterial, 459, 474–475  
   metastatic, 494, 532f  
   risk for, 495b
- Endoplasmic reticulum, 164  
   and exocytosis, 165b  
   signaling, 164  
 Endostatin, 214–215  
 Endosymbiotic *Wolbachia* bacteria, 481, 482f  
 Endothelial dystrophies, 517–518  
 Endothelin, 386  
 Enterohepatic circulation, 343–344  
 Environmental causes, of congenital malformations, 129.e4  
 Enzymes, conjugating, 349b  
 Eosinophil(s), 376f, 379  
 Eosinophil cationic protein (ECP), 448  
 Eosinophil major basic protein, 448  
 Epidermoid cysts, 537  
 Epigenetic development, 110  
 Epigenetic inheritance, 158.e1, 158.e1f  
 Epigenetics, 135, 141, 141b  
 Epigenome, 159  
 Epinephrine, 225, 359.e1  
   intraocular pressure, 358  
   sympathetic system, 357, 357f  
   synthesis of, 358f  
 Episclera, 21, 22f  
 Episcleritis, 456  
 Epithelioid haemangioma, 534  
 Epithelium  
   corneal  
     drug administration in, 349–350  
     permeability of, 349–350  
   dystrophies of, 516  
   embryology, 108–110  
 Epitopes, 373, 397  
   mapping, 430  
 Epstein-Barr virus, 519–520  
 ER-mitochondria organizing network (ERMIONE), 164–166  
 ER stress, 164.e3, 164.e3f  
 Erythrocyte, 376f  
 Erythropoietin, 448  
 Esterases, 349b  
 Etanercept, 365–366  
 ETDRS chart, 280–282  
 Ethambutol, as oculotoxic drug, 369  
 Ethmoidal canals, 2  
 Ethmoidal sinuses, 4f, 8f, 7.e1  
 Exfoliation syndrome, 508  
 Exocytosis, 165b, 165f  
 Exome sequencing, 146  
 Exons, 132–133  
 Exosomes, 165b, 165f  
 Experimental autoimmune uveoretinitis, 459  
 Extracellular matrix (ECM), 178–189  
   glycosaminoglycans, 186, 187b  
   mesenchymal cells binding, 189, 188.e1, 188.e2f  
   molecules, cell adhesion, 186–188  
   non-structural proteins, 184–186  
   proteins, 178–184, 179b, 179f  
   remodelling, 392

Extradural haematomas, 13b  
 Extrageniculostriate pathway, 331–332, 333f  
 Extranodal marginal zone lymphoma (EMZL), 535  
 Extraocular muscles, 64, 65f–66f  
   anatomical features of, 67t, 70f  
   development of, 129  
   fibre classification of, 70t  
   insertions of, 69f  
   origins of, 68f  
 Eye  
   anatomy of, 1–102  
   fibrous coat of, development of, 119–120  
   microbial infections of, 462–485  
   shape, size and position of, 13–14  
   structure of, 13–61, 14f  
 Eye field, frontal. *see* Frontal eye field  
 Eye field transcription factors, 110–111, 111f  
 Eye movements, 286–287  
   binocular, 327–329  
   compensatory, 335  
   conjugate, 327  
   control, 329–334  
     superior colliculus, 331–333  
   convergence, 327  
   horizontal, 333–334  
   mechanical control, 335–336  
   natural activity, 335, 336f  
   neural control, 335–336  
   physiology, 326–336  
   rapid 'reflex' locking-on, 332  
   reflex, 330–331, 332f  
   regulation of complex, 333–334  
   rolling, 330  
   rotational, 326  
   torsional, 326, 329  
   tracking, 310  
   types, 326–329  
   unioocular, 326  
     *see also* Saccades  
   voluntary (VOL) and involuntary (INVOL), 310f  
 'Eye shine', 56b, 56f  
 Eye worm, 482, 483f  
 Eyelashes, 82, 202, 129.e4  
   hair follicles, 202  
 Eyelids, 82–83, 83f  
   ageing changes in, 83b  
   autoimmune disease of, 501  
   blood and nerve supply of, 83, 86f  
   cysts, 537  
   development of, 129.e4  
   granulomatous, 500  
   margins of, 82, 83f–85f  
   movements of, 83  
   muscles of, 77–82  
   phakomatous choristoma, 522  
 Ezrin, 255

## F

Face  
   development of, 129.e4, 129.e5f  
   muscles of, 77–82  
 Facial defects, congenital, 129.e6b  
 Facial nerve, 77, 81f  
   lesions of, 80b  
   reflexes involving, 82t  
 Facial skeleton, 1  
 FACIT (fibril-associated collagens with interrupted triple helices)  
   collagens, 180–182, 180t  
 False projection, 313  
 Falx cerebri, 12, 12.e1  
 Family pedigree, 137–138, 137.e1f  
 FAS ligand, 147b  
 Fasciculus, medial longitudinal, 69  
 Fatty acids, polyunsaturated, 195–197  
 Fatty degeneration, 506  
 FCO1 gene, 238  
 Fibrillin, 183, 183f, 185–186  
 Fibrin, 387–388  
 Fibrinolysis, 492–493, 500  
 Fibroblast growth factor (FGF), 120–121, 250  
 Fibronectin, 179, 179f, 184–185, 188.e1, 184.e1, 188.e2f, 184.e1f  
   and fibrin, 184–185  
   lens capsule, 234  
   retinal, 253–254  
   in reverse integrin-mediated cell signaling, 184–185  
 Fibrosis, 394  
 Fibrous coat, 14  
   development of, 119–120  
 Fick's law, 340  
 Filarial nematodes, 463t  
 First-pass metabolism, 339  
 Fixation reflex, 329  
 Flat midget bipolar cells, 46  
 Fleurettes, 531  
 Flexner-Wintersteiner rosettes, 531, 531f  
 Flicker, 301–302  
   limits of vision, 271  
 Flicker photometer, 302  
 Flow cytometry, 147  
 Fluorescent resonance energy transfer (FRET), 145  
 Flurbiprofen, 362–363  
 Focal adhesion proteins, 189  
 Follicular lymphoma, 535  
 Foramen lacerum, 10t  
 Foramen ovale, 10t  
 Foramen rotundum, 10t  
 Foramen spinosum, 10t  
 Forebrain, 103  
 Form  
   discrimination, 273  
   perception, 324–325  
 Foscarnet, 352.e1b  
 Fovea  
   depression, 115–117  
   development of, 115–117  
 Fovea centralis, of retina, 39  
 Fragile sites, 130  
 Fragile X syndrome, 137b  
 Frameshifts, 137b  
 Free radical scavenger, vitamin E, 198  
 Free radicals, 193–194, 193f, 200.e1  
   cataract formation, 238–239  
   damage, and lens, 239b, 239f  
   detoxification of, 193t  
   generation of, 164.e3, 164.e3f  
   host response to injury, 383  
   from hydrogen peroxide, 194b, 194f  
 Frequency of seeing, 274  
 Frontal eye field, 96, 97f  
 Frontal sinuses, 5f, 8f, 7.e1  
   development of, 129.e4  
 Fronto-nasal process, 129.e4  
 Fuchs' endothelial dystrophy, 518, 519f  
 Fuchs' heterochromic cyclitis, 459  
 Fundus flavimaculatus, 515, 516f  
 Fungal infections, 475–477  
 Fungal keratitis  
   contact lens-associated, 475  
   pathogenesis of, 475–477, 476f  
   treatment of, 475  
 Fungi, inflammatory disease and, 497–498  
 Fusion supplement, 327

## G

G-banding, 130  
 G-proteins, in second messenger activity regulation, 345b  
 Galea aponeurotica, 81  
 Gametes, 103.e2  
   formation of, 131–132  
 Ganciclovir, 352.e1b  
 Ganglion cells, in retina, 43f, 46–48, 47f  
   diffuse, 48  
   midget, 47f, 48  
 Gap junctions, 189, 172.e1, 172.e1f  
   lens semipermeable membranes, 229, 230f, 234  
 Gap phases, 130–131  
 Gene(s), 130  
   candidate identification, 150  
   cloning, 142  
   components of, 133f  
   decoding DNA, 133–135  
   downstream, 110  
   finding and tracking, 146  
   frequency of, 140  
   in ocular development, 109t  
   ocular disease-causing, 152t  
   regulation of expression, 135  
 Gene arrays, 143–145, 144f, 145b  
 Gene augmentation therapy, 147  
 Gene expression, cascade of, 110  
 Gene gun, 147



- Gene loci, 130  
 linkage of, 140–141  
 retinal disorders, 153f
- Gene mutations, 135–137  
 screening for, 150
- Gene probes, 146
- Gene therapy, 147–148  
 vectors in, 148b
- Generator potentials, 287–288, 289b, 289f
- Genetic abnormalities, 488–489
- Genetic linkage, 140–141
- Genetic makeup, 132
- Genetic mutations, somatic, 439
- Genetic polymorphisms, 139
- Genetics, 130–156  
 clinical, 137–139  
 molecular, 132–135, 150–156, 152t  
 population, 140–141
- Geniculate bodies, lateral. *see* Lateral geniculate bodies
- Geniculocalcarine tracts, 93f, 95, 96f
- Genome, stability of, 169
- Genome-wide association studies (GWAS), 143–145, 145b
- Genomics, 143–145, 144f, 159
- Giant cell angiofibroma, 534
- Giant cell arteritis, 503, 503f
- Glaucoma, 26b, 61b, 512–513  
 carbonic anhydrase inhibitors for, 359  
 closed-angle  
   primary, 512–513  
   secondary, 513  
 congenital, 127b, 513–514  
 exfoliation syndrome and, 508  
 infantile, 127b  
 intraocular pressure control in, 359  
 iridocorneal endothelial syndrome, 518  
 lens particle, 502  
 narrow-angle, 356–357  
 neurovascular (rubeotic), 513  
 open-angle  
   primary, 512, 513f  
   secondary, 513  
 phakolytic, 502  
 rubeotic, 513  
 secondary, 513, 513f  
 from steroid ocular toxicity, 369  
 topically applied drugs for, 360b
- Glioma, 531–533, 533f
- Glomerular filtration, 343
- Glucocorticoids, 363–364
- Gluconeogenesis, 190
- Glucose  
 facilitated diffusion of, 190  
 protein glycation, 190f, 191, 192f  
 tissue glycation, 189–193
- Glucose-6-phosphate dehydrogenase  
 enzyme deficiency, 346–347
- Glucose metabolism  
 and cellular metabolism, 191  
 and lipid metabolism, 193
- Glucose transporters (GLUTs), 190, 235, 190.e1, 190.e1f  
 in glucose homeostasis, 194.e1f
- Glutamate, 243–244, 265t  
 cell depolarization, 344–345  
 receptors of, 265–266  
 retinal neurotransmitter, 265–266, 266f  
 retinal receptor binding to bipolar cells, 265
- Glutamate-receptor blocking agents, 360b
- Glutamine, and disc shedding, 247, 248f
- Glutathione  
 redox systems involving, 209–210  
 in redox systems of lens, 234b, 234f, 236
- Glutathione peroxidase, 252–253
- Glutathione-S-transferase, 193–194, 195f, 220
- Glutathione SH, 237
- Glycine, amacrine cells, 265–267
- Glycosaminoglycans  
 in cornea, 16–18, 120, 186  
 extracellular matrix, 186  
 in lens, 33  
 in sclera, 21, 187b, 205–206  
 structure of, 187b, 187f
- Goblet cells  
 in conjunctiva, 86f–87f, 88, 200–201  
 epithelial, 202
- Golgi apparatus, 164, 375f  
 and exocytosis, 165b  
 signaling, 164
- Golgi complex, conjunctival epithelium, 202
- Goniodysgenesis, 127b
- Gorlin-Goltz syndrome, 523
- Grafts, 450  
 rejection, 450–451
- Gram-negative bacteria, 463t
- Gram-positive bacteria, 463t
- Granules, 375f
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 214, 402
- Granulocytes, 378–380  
 neutrophilic, 377
- Granulomas, 411
- Granulomatous inflammation, 499–500
- Grating frequency, 284
- Graves' ophthalmopathy, fibrosis of, 394
- Gray, 487
- Growth factor  
 corneal, 214  
 from retinal pigment epithelium, 255
- Guanine triphosphate (GTP), 345, 345b
- Guanylate cyclase, 261, 263f
- Gut-associated lymphoid tissue (GALT), 416
- H**
- H<sub>1</sub>-receptors, 360
- H<sub>2</sub> antagonists, 361
- Haemangioma, 521, 534  
 epithelioid, 534
- Haemangiopericytoma, 534
- Haematopoietic stem cells, 412–413
- Haemoglobin glycation, 191–193, 192f
- Haemopoietic stem cells, in cornea, 207
- Haemorrhage, 509
- Hallerman-Streiff syndrome, 129.e5b
- Hamartomas, 521–522  
 astrocytic, 532f
- Haplotype, allelic differences, 426b, 426f
- Hard exudates, 509, 509f
- Hardy-Weinberg equilibrium, 140
- Hassall-Henle warts, 518
- Hassall's corpuscles, 413–414
- Heavy (H) chain, 440f
- Helminths-nematodes, 463t
- Hemianopia  
 contralateral homonymous, 100f, 102f  
 ipsilateral nasal, 99f  
 pupil size, 286
- Hemidesmosomes, 14–15, 174, 189, 189t  
 in corneal epithelium, 203
- Henderson-Hasselbalch equation, 340
- Heparan, 187, 187f
- Heparan sulphate, 226
- Hereditary causes, of congenital malformations, 129.e4
- Hering's colour-opponent scheme, 306
- Herpes simplex ophthalmicus, 495
- Herpes simplex virus (HSV)  
 acute renal necrosis, 496  
 keratitis, 462, 495, 496f
- Herpes simplex virus 1 (HSV-1), 471
- Herpes stromal keratitis, 471–472  
 angiogenesis and lymphangiogenesis, 471  
 latency of, 471–472, 472f  
 primary infection, 471
- Heterozygotes, 137, 140
- High endothelial venules (HEVs), 418
- High-resolution banding, 130
- Histamine  
 inhibition of, 360–361  
 release from mast cells, 360
- Histamine receptor antagonists, 360b
- Histaminergic system, 359–361
- Histidine-rich glycoprotein (HRG), 185
- Histones, 135
- HLA-A29, 139
- HLA-B27, 139, 425  
 acute anterior uveitis, 459
- Homeobox, 110
- Homeostasis, and intermediate filaments, 174, 176f
- Homeotic genes, 110
- Homer-Wright rosettes, 529, 531f
- Homocystinuria, 504–505
- Homozygotes, 137

- Hordeolum, 83b  
 Horizontal cells, 266–267  
   feedback, 292f, 294–295  
   ON/OFF microcircuitry, 291  
   in retina, 43f, 47f, 48–49  
 Horizontal gaze centre, 330–331, 332f  
 Horner syndrome, 85b, 357.e1b  
 Horopter, 313–314, 315b, 315f  
 Host defences, at ocular surface, 463–469  
 Host response, injury, 382–395  
*Hox* genes, 110, 124  
   retinoic acid, 129.e6  
 Hue-discrimination curve, 272, 272f  
 Hues, 272  
   discrimination, 303  
 Human genome  
   DNA analysis, 142–146  
   haploid, 132–133  
   mutations within, 137b  
 Human leucocyte antigens (HLA), 139, 141  
   antigen presentation, 432  
   disease susceptibility, 425  
 Human papillomavirus, 519–520  
   E6 gene, 451–452  
 Huntington's disease, 137b  
 Hyalinization, 505–506, 508, 508f  
 Hyalocytes, 38, 39f  
 Hyaloid artery, 104f–105f, 106–108  
   development of, 117, 121  
 Hyaloid canal, 117  
 Hyaloid fossa, 37, 37f  
 Hyaloid system  
   development of, 121–124  
   malformations of, 124b  
 Hyaluronan, 123, 186  
 Hyaluronate receptor, 253–254  
 Hyaluronic acid, 186, 186f, 215  
   in aqueous humour, 223, 226f  
   in vitreous, 240–241  
 Hydrogen peroxide, 194, 194b, 194f, 209–210, 200.e1, 200.e1f  
   ciliary body, 221  
   detoxification by trabecular meshwork, 227  
   host response to injury, 383  
   and iron, 253  
 Hydropic swelling, 490  
 3-Hydroxy-kynurenine, 238–239, 248b  
 Hydroxyamphetamine, 359.e1  
 Hydroxycholesterols, 197  
 Hydroxyeicosatetraenoic acids (HETE), 197, 197b, 197f  
 Hydroxyoctadecadienoic acids (HODE), 197  
 5-Hydroxytryptamine (5-HT), 363  
 5-Hydroxytryptamine (5-HT) antagonists, 363  
 Hyperacuity, 280, 282  
 Hypercapnia, and retinal blood flow, 246  
 Hyperglycaemia, chronic, 191  
 Hyperopia, 209.e1  
 Hyperoxia, and retinal blood flow, 246  
 Hyperparathyroidism, 507  
 Hyperpolarization response, 263–264, 288, 291  
 Hypertension, 510  
 Hypertrophy, 490  
 Hypervitaminosis D, 507  
 Hypochlorous acid (HOCl), 385f  
 Hypophyseal fossa. *see* Pituitary fossa  
 Hypophysis cerebri, 9  
 Hypothalamus, 'place' cells, 310  
 Hypovitaminosis A, 354  
 Hypoxia-inducible factor, 392–393  
 Hypoxia-inducible factor-1, 190
- I**  
 Ibuprofen, 362–363  
 Idiopathic orbital inflammation, 538, 538f  
 Iliivien@, 351  
 Image disparity, 317, 313.e1f  
 Image fusion, 313  
 'Image stabilization', 309  
 Immediate hypersensitivity, 381  
 Immune cells, activation of innate, 389–390  
 Immune complexes, 416–418  
 Immune response, 370  
   acute, 382–392  
   adaptive, cytokines, 399–404  
   innate, 382–395  
     cytokines, 399–404  
     interferons, 401–402  
     interleukins, 401–402  
     primary, 372  
     tumours induce, 451–453  
 Immune system, 370–373, 416–421  
   acquired, 370–371  
   adaptive, 453–454  
   in ageing and degeneration in eye, 460–461  
   cells, 373–382, 375b–376b  
   effector mechanisms, 396–412  
   evolution, 372  
   eye, 453–461  
   host-defence of, 371  
   innate, 370–371  
     and eye, 453  
   molecules of, 373–382  
   mucosal, 416  
   organization of, 412–421  
   parasitic infections, 444–445  
   surveillance, 416  
   tissues, 375b–376b, 377–378  
 Immunity, 370  
   acquired, 380–381  
     development, 372  
   active, 372  
   cell-mediated, 411  
   innate, 377–380  
     collectins, 407b, 407f  
     complement, 407b, 407f  
     mast cell, 448–450  
       mediate, 390–392  
   passive, 372  
 Immunization  
   active, 372  
   passive, 372  
 Immunoglobulin(s)  
   isotypes of, 397, 398b, 398f  
   superfamily of proteins, 428b, 428f  
 Immunoglobulin A (IgA), tears, 380–381, 453–454, 463  
 Immunoglobulin E (IgE), 379  
   in hypersensitivity response, 360  
   mast cell degranulation, 447  
 Immunoglobulin G (IgG), tears, 463  
 Immunohistochemistry, 535b  
 Immunological memory, 395–396  
 Immunological synapse, 434f, 436f  
   cell signalling, 423–424, 435–437  
 Immunological tolerance, 439–445  
   B cell, 443–444  
   failed, 444–445  
   induction mechanism, 442–443, 442.e1  
   T cell, 443–444  
 Immunology, 370–461  
 Immunopathology, of tissue reactions, 420t  
 Immunoreceptor tyrosine-based activation motifs (ITAMs), 435–436  
 Immunosuppressive agents, 364–366, 459–460  
   genetic control of, 347b  
   mode of action of, 364b  
   side effects of, 365b  
 In situ hybridization, 146, 496, 497b, 497f  
 Indometacin, 362–363  
 Infants, visual acuity testing, 286  
 Infections  
   *see also* Fungal infections  
   barriers, 453  
   in developing countries, 480–483  
   epithelium, as barrier for, 463–464  
   helminth, 480  
   inflammation and, 494–499  
   innate immunity to, 469  
   microbes in environment, 462–463  
   microbial, 462–485  
   ocular, 469–480  
   physical barriers for, 463  
   protozoan, 477–480  
   pyogenic, 494, 494f  
 Inflammation, 492–504  
   acute, 492–494, 493f  
   chemical mediators, 492–493  
   chronic, 393–394  
   contact lens-related, 474  
   due to autoimmune disease, 500–504  
   effector cells, 392  
   granulomatous, 499–500  
   idiopathic orbital, 538, 538f

- infection causing, 494–499
  - intraocular, 459–460
  - non-granulomatous, 500
  - phagocytosis, 389
  - resolution of, 392–393
  - systemic response, acute, 394–395
  - vascular changes, 386
  - without infection and, 499
  - Inflammatory disorders
    - chronic, 394
    - endogenous material reactions, 500, 500f
    - exogenous non-biological materials reactions, 500
    - orbital, 456–457, 458f
    - scleral, 456–457, 458f
    - viruses and, 495–497
  - Inflammatory mediators, 383
  - Inflammatory response, 462
    - acute, 382–392
    - phases, 382–392
    - tissue damage, 382–383
    - vascular changes, 386
  - chronic, 412
  - stages of, 393f
  - Infliximab, 365–366, 367f
  - Information processing, hierarchical organization, 325
  - Infranuclear lesions, of facial nerve, 80b
  - Infratentorial compartment, 12.e1
  - Inheritance
    - autosomal, 137–138
    - Mendelian, 138b
    - mitochondrial, 138, 156
    - multifactorial, 138–139
    - ocular disease, 152t
    - X-linked, 137–138
  - Injury, host response, 382–395
  - Innate immunity, to microbial infection, 469
  - Innate lymphoid cells, 382
  - Inositol triphosphate (IP<sub>3</sub>), 261
  - Instantaneous parallax, 316–317, 317f
  - Insulin, 190
  - Insulin-like growth factor-1 (IGF-1), 244–245
    - receptor, 250
  - Integrin, 160, 160f, 182, 188, 188.e1
    - binding to extracellular matrix proteins, 188t
    - receptor, 185f, 189
  - Integrin  $\alpha_v\beta_3$ , 246, 255, 261–262
  - Integrins, 386
  - Intercellular adhesion molecule 1 (ICAM-1), 253–254
  - Interferon  $\alpha$ , 404f
  - Interferon-regulating factors, 403.e2
  - Interferons, 401–402, 403.e1–403.e2
  - Interleukin-1, 403.e1
  - Interleukin-2, 403.e1
  - Interleukin-4, 403.e2
  - Interleukin-6, 403.e2–403.e3
  - Interleukin-8, 403.e3
  - Interleukin-10, 403.e3
  - Interleukin-12, 403.e3
  - Interleukin-15, 403.e3
  - Interleukin-17, 403.e3
  - Interleukin-18, 403.e3
  - Interleukin-21, 403.e3
  - Interleukin-27, 403.e3, 403.e5f
  - Interleukin-32, 403.e3
  - Interleukin-33, 403.e4
  - Interleukin-34, 403.e4
  - Interleukin-36, 403.e4
  - Interleukin-37, 403.e4
  - Interleukin-38, 403.e4
  - Interleukins, 214, 401–402
  - Intermediate filaments, 173–174
    - classes of, 174
    - distribution of, 175f
    - stress response, of cells, 176f
  - Intermembrane space, in mitochondria, 164–166
  - Interphotoreceptor binding protein (IRBP), 41–45
  - Interphotoreceptor matrix, 41–45
  - Interphotoreceptor retinol-binding protein (IRBP), 253–254
    - and retinoid transport, 257
  - Intracellular matrix, 165b, 168b, 169–177
  - Intraocular pressure, 223f
    - adrenergic receptor regulation, 225
    - aqueous humour dynamics, 222
    - and cAMP levels, 225
    - control of, 358–359
    - and guanylate cyclase, 225
    - M<sub>3</sub> muscarinic receptors and, 223–225
    - and melatonin, 225
    - and nucleotides, 225
  - Intraparietal sulcus (IPS), 325.e1f
  - Intraretinal space, 108–110
  - Intravitreal delivery, of drugs, 352–353
  - Intravitreal inserts, 351
  - Intravitreal therapy, 353f
  - Introns, 132–133
  - Invaginating midjet bipolar cells, 46
  - Inversion, 136
  - Ion channels, 344–345
  - Ion exchanger, collagen as, 350–351
  - Ionizing radiation, 487
  - Iontophoresis, ocular, 352
  - Iridocorneal endothelial syndrome, 518
  - Iridogoniodysgenesis, 127b
  - Iris, 26–30, 27f, 216–217
    - anterior border layer of, 26–28, 27f, 29f
    - blood flow in, 216–217, 217f
    - blood supply of, 28
    - capillaries, 28
    - collagens, 182
    - development of, 125f–126f, 126–127
    - dilator pupillae muscle of, 28, 126
    - eicosanoids in, 220
    - epithelium, 126
    - functions of, 216
    - hypoplasia, 120b
    - innervation, 126–127
    - melanomas, 526
    - microscopic anatomy of, 26–28
    - nerve supply of, 30
    - neuromuscular junctions of, 216
    - physiology of, 216
    - pigment epithelium of, 28
    - pigmentation of, 126
    - smooth muscles of, 126
    - sphincter pupillae muscles, 126
    - stroma of, 28, 29f
    - structure of, 26, 27f
    - transillumination, 155
    - trauma response, 492
  - Iris naevus syndrome, 518
  - Iritis, antimuscarinic agents for, 356–357
  - Iron homeostasis, 253, 253f
  - Irradiation therapy, complications of, 488b, 488f
  - Irvine-Gass syndrome, 359.e1
  - Isoprostanes, 197, 197b, 197f
  - Isotype switching, 397
- J**
- Jak-STAT pathway, 404f
  - Jaundice, bilirubin deposition in, 21b
- K**
- Kaposi sarcoma, 534
  - Kayser-Fleischer rings, 489b
  - Kearns-Sayre syndrome, 156, 490b
  - Keratan sulphate, 186–187, 187f, 226
    - in cornea, 205
  - Keratin, 174, 203
    - in conjunctival epithelium, 202
  - 'Keratinoid', 517
  - Keratitis, 455–456
    - Acanthamoeba*, 477–478, 477f, 498–499
    - disciform, 495
    - herpes simplex virus, 495, 496f
    - herpes stromal, 471–472
    - postherpetic disciform, 455–456
  - Keratoblasts, 119–120
  - Keratocan, 205
  - Keratoconjunctivitis sicca, 354, 456–457
  - Keratoconus, 209
  - Keratocytes, 16–18, 17f–18f
    - corneal, 207
    - metabolism of, 209
    - specialization, loss of, 212–213
  - Ketone reductase, 349b
  - Kinetochore engineers chromosome, 174
  - Klinefelter syndrome, 136.e1
  - Knudson's two-hit hypothesis, 154–155

- L**
- Lacrimal apparatus, 89–92, 89f  
collecting portion of, 90f, 91–92
- Lacrimal component, of orbicularis oculi, 77–80
- Lacrimal fossa, 2
- Lacrimal gland, 89–91  
adenocarcinoma, 537  
blood supply of, 91  
development of, 129.e4  
histological structure of, 89–91, 90f  
inflammatory disease of, 456–457  
nerve supply of, 91, 91f  
secretion, 199–200  
tumours, 536–537
- Lacrimal puncta, 82, 91–92
- Lacrimal sac, tumours, 537
- Lacrimation, excess, 91
- Lacritin, ocular infection barrier, 463
- Lactic acid production, in retina, 242–243
- Lactoferrin, 200, 209  
ocular infection barrier, 453, 463
- Lacus lacrimalis, 82
- Lamina cribrosa, 59–61
- Lamina fusca, 21, 22f
- Lamina vitrea, 55, 56f–57f
- Laminin, 179, 179f, 183, 244–245, 208.e2  
of the internal limiting membrane (ILIM), 184  
isoforms of, 183  
structure of, 208.e2f
- Lamins, 174
- Langerhans' cells, 416
- Laser in situ keratomileusis (LASIK), 213
- Lasers, in ophthalmology, 487t
- Latanoprost, 360b
- Lateral geniculate bodies, 93f–94f, 94–95
- Lateral geniculate nucleus (LGN), 269–270
- Lattice dystrophy, 516
- Leber's hereditary optic atrophy, 490b
- Leber's hereditary optic neuropathy, 156
- Lectins, 405
- Leiomyoma/leiomyosarcoma, 533
- Lens, 32–35, 34f, 228–240  
ageing in, 237–240  
changes, 36b  
capsule, 33, 106–108, 234  
development of, 121  
changes in, 230f  
collagens, 182  
cytoskeletal proteins of, 232–233  
development of, 120–121, 122f–123f  
epithelium, 33, 34f  
anterior, 121, 123f  
function, 228  
equatorial, 229  
fiber cell organization, 228–230, 229f–230f  
fibres, 33–35, 34f  
free radical damage and, 239b, 239f  
insult, 238  
intra-lens microcirculation, 244b  
lipids, 236, 237f  
malformations of, 121b  
membrane lipids and proteins of, 233  
metabolism in, 235–237  
microcirculation in, 229f–230f, 234  
physiology of, 234–235, 244b  
placode, 104f–105f, 106, 120–121, 122f–123f  
position of, 33  
proteins, 235–236  
carbamylation of, 239–240  
redox systems in, 236–237  
semipermeable membranes of, 234–235  
shape of, 33  
size of, 33  
structure of, 33–35, 34f, 230.e1f  
transparency of, 228–235, 228f  
trauma response, 492
- Lens bow, 33, 34f
- Lens cavity, 120–121, 122f–123f
- Lens fibres  
primary, 108–110, 121, 123f  
secondary, 121, 123f
- Lens-induced uveitis, 501–502, 502f
- Lens pit, 104f–105f, 106–108
- Lens pore, 120–121, 122f–123f
- Lens vesicle, 104f–106f, 106–108, 120–121, 122f–123f
- Lens zonules, 30, 35, 36f  
accommodation in, 35  
chambers in, 35–37, 37f
- Lenticular fossa, 37, 37f
- Leptomeninges, 9
- Leptotene, 131
- Leucocyte  
activation, 386  
adhesion  
to each other, 418–419  
to endothelium, 386–387, 387f, 388t  
sequence of events in, 387f  
migration, 387–389  
tears, 453
- Leukotrienes, 361–362, 362b
- Levator palpebrae superioris, 81–82
- LFA-1, 435
- Li-Fraumeni syndrome, 520–521
- Lids, 202–203  
closure of, 202  
lacrimal glands in, 202  
movement, 202  
control of, 202  
mucus-secreting glands, 202
- Ligand-gated ion channel, 355
- Ligand-receptor affinity, 346
- Ligand selectivity, 346
- Light  
physical behaviour, 282  
reflectance, 319  
sensing, 270–271
- Light adaptation, 275  
cone thresholds, 303–304
- Light (L) chain, 440f
- Light detection, 273–279  
threshold, 277–278
- Light energy  
measurement, 278b  
quanta, 273–274
- Light exposure, 486–487
- Light reflexes, pupillary, 286, 286b, 286f
- Light rise, 298, 298b, 298f
- Limbus, 21–26, 23f  
anatomical and surgical, 24b
- Liminal brightness increment (lbi), 304
- Limiting lamina  
anterior. *see* Bowman's layer  
posterior. *see* Descemet's membrane
- Line orientation, 312
- Lingual gyrus, 95
- Linkage analysis, 140–141
- Linkage disequilibrium, 141
- Linkage equilibrium, 141
- Lipid(s)  
abnormalities, 354  
antigen presentation, 432  
membranes, oxidation of, 197b, 197f  
metabolism, 193  
peroxidation, 193f, 194–198, 197b  
retinal, 245  
structure of, 196b, 196f  
tear, 453  
tear film, 198–199, 199f
- Lipid bilayer, 162f, 163–164, 197f  
formation of, 195
- Lipid deposition, 506
- Lipid phosphatase (PTEN), 255
- Lipid rafts, 161–163
- Lipocalin, ocular infection barrier, 463
- Lipofuscin  
accumulation, 261–262  
and photoreceptor renewal, 261–262
- Lipopolysaccharide, 389
- Liposomes, 351–352
- Lipoxidation, 197
- Lisch nodules, 489b
- Listing's law, 330, 331f, 335
- Loa loa, 482, 499
- Local anaesthetics, 366–368  
excitable membrane effects of, 366–368  
regional, maximal safe doses of, 368b  
side-effects of, 368  
topical, 367
- Localized amyloid deposition, 507–508, 508f
- Lod score, 140–141
- Lodoxamide, 361
- Loiasis, 482, 483f
- Lumican, 205
- Luminance  
contrast sensitivity, 284  
visual acuity, 280, 286
- Luminosity, 302–303

- Lutein, 253, 254f  
 Lyme disease, 494–495  
 Lymph nodes, 414f  
   for antigen trapping, 414–415  
 Lymphatic system, 415  
 Lymphocytes, 419–420, 419f  
   activated, 418  
   in conjunctiva, 88  
   conjunctival intraepithelial, 202  
   effector cells in inflammation response, 392  
   inflammatory reactions of, 500  
   switching off, 420  
   thymic education, 442  
 Lymphocytic perivascularitis, 500  
 Lymphoid cells, innate, 382  
 Lymphoid hyperplasia, benign, 535  
 Lymphoid organs, functional anatomy, 412–416  
 Lymphoid system, 380–381  
   trafficking of cells to, 418–419  
 Lymphoid tissue inducer cells, 381–382  
 Lymphokine-activated killer (LAK) cells, 452  
 Lymphoma, 534  
 Lymphomyeloid cells, development of  
   primary sources of, 412–413  
 Lyonization, 138b  
 Lysosomes, 492–493  
 Lysozyme, 453  
   ocular infection barrier, 463  
 Lysyl oxidase, 227  
 Lytic granules, 375f
- M**  
 M cells, 291, 305–306  
   contrast sensitivity, 284–285  
 Macrophages, 375f, 377, 411, 377.e1f  
   activated, 392  
   in cornea, 207, 464  
   granulomatous reactions of, 494–495, 495f  
   from myeloid and lymphoid precursors, 378b, 378f  
   professional phagocytes, 389  
 Macrovascular occlusion, 510–511  
 Macula  
   development of, 115–117  
   false, 313  
 Macula lutea, 39  
 Macular degeneration  
   age-related, 58b, 460f, 513–514, 514b, 515f  
   complement activation, 409–410, 410f  
   disciform, 513–514  
 Macular dystrophy, 516–517, 517f  
 Macular oedema  
   cystoid, 359.e1  
   rheumatoid disease, 501  
 Maculopapillary bundle, 59  
 Maculopathies, hereditary, 153  
 Magnetic resonance imaging, functional (fMRI), 321, 325  
 Magnetoencephalography, 321  
 Magnocellular pathways, 321–322  
 Major histocompatibility complex (MHC), 15–16, 372, 424–427  
   alleles, 425  
   antigen presentation, 423–424, 432, 422.e1f  
   antigen recognition, 421  
   class II-peptide complexes, 397  
   gene cluster, 424–425  
   gene map, 425b, 425f, 403.e4b–403.e5b  
   extended, 425.e1, 425.e1f  
   gene regulation/transcription, 427  
   genes, 425b, 426–427  
   innate immunity, 390  
   peptide, 423.e1  
   polymorphisms, 425  
 Major histocompatibility system, 424–427  
 Malabsorption syndromes, night blindness, 258–259  
 Malignancy  
   epithelial tumours, 523–525  
   lacrimal gland tumours, 536–537  
   lymphoid tumours, 534–536, 535f  
   peripheral nerve sheath tumours, 529  
 Malignant melanoma, 521, 525–526  
   enucleation, 526  
   histological classification, 526, 529f  
   treatment, 526  
   uveal, 525–526, 527f  
 Malignant transformation, 519  
 Malnutrition, night blindness, 258–259  
 Mammalian target of rapamycin (mTOR), 164, 164.e3, 164.e3f  
 Mandibulofacial dysostoses, 129.e5b  
 Mannan-binding lectin (MBL), 405  
 Marfan syndrome  
   ectopis lentis, 35b  
   fibrillin mutations, 185–186  
 Marx's line, 201  
 Mast cell(s), 376f, 378–379  
   activation, 446f–447f, 447  
   allergic disease, 447  
   in choroid, 58f  
   connective tissue, 379, 446–447  
   degranulation, 447–448  
   histamine release from, 360  
   immune response, 448–450, 449f  
   isotype switching, 448f  
   mucosal, 379, 446–447  
   types, 447  
 Maternal age, 129.e4  
 Matrilysin, 214  
 Matrix metalloproteinases (MMPs), 185, 214, 384t, 208.e2  
   host response to injury, 383  
   structure of, 384f  
 Matrix sheath, insoluble, 219f, 254  
 Mature B lymphocyte, 375f  
 Mature T lymphocyte, 375f  
 Maxillary nerve, 75, 78f–80f  
 Maxillary sinus, 4f, 8f, 7.e1  
 Mean channel lifetime, 344–345  
 Measuring by eye, 311–312  
 Megakaryocyte, 376f  
 Meibomian gland duct, blocked, 500  
 Meibomian glands, 202, 129.e4  
   inflammation of, 354  
 Meiosis, 131–132  
 Melanin  
   albinism, 155f  
   drug binding, 368  
   retinal pigment epithelium, 108–110, 253, 256–258  
 Melanocytes, iris, 126–127  
 Melanomas, cutaneous, 147b  
 Melanopsin, 247, 250–251, 251f  
 Melanosis, primary acquired, 525  
 Melanosomes, 155  
 MELAS syndrome, 490b  
 Melatonin, 221  
   circadian rhythms, 267, 276–277  
   disc shedding, 247, 248f  
   function, 276–277, 277f, 277.e1f  
   and intraocular pressure, 225  
   production regulation, 296  
   synthesis and secretion, 276  
 Membrane attack complex (MAC), 408  
 Membranous bones, 129.e1  
 Memory  
   shape detection, 320  
   spatial constancy, 310  
 Memory B cells, 420  
 Memory T cells, 419  
 Mendelian randomization, 141  
 Meningeal arteries, 11f–12f, 12, 7.e2f  
 Meninges, 9–13, 11f–12f, 9.e1f  
 Meningitis, 62b  
   neck rigidity and, 12.e1  
 Mercapturic acid pathway, 236  
 Mesencephalic nucleus, 77  
 Mesenchyme, 103, 104f–106f, 108–110, 106.e1b  
   corneal development, 119–120  
   fronto-nasal process, 129.e4  
   nasolacrimal duct, 129.e4  
   neural crest derived from periocular, 111–112  
   periocular, 113f  
 Mesoderm, paraxial, 112, 114f, 129  
 Messenger ribonucleoprotein particles (mRNPs), 169, 171f  
 Messenger RNA (mRNA), 133b, 135  
   gene probes, 146  
   Northern blotting, 142  
 Metabolic disease, 504–505  
 Metalloproteinases, 501  
 Metaphase, 131–132  
 Metaplasia, 490

- Metastases, 521  
skeletal, 507
- Metastatic tumours, 537
- Metazoal infection, inflammatory, 498–499
- Methotrexate, 364b
- Methysergide, 363
- Metzincin proteases, 384f
- Micro-RNA, pathway of, 136f
- Microaneurysms, 509
- Microbes, in environment, 462–463
- Microbial infections, of eye, 462–485
- Microbiome, 159, 374b, 374f
- Microfilaments, 169–173, 172.e1b  
actin bundles in, 172  
in exocytosis, 165b, 169–173  
proteins associated with, 172–173, 173t
- Microglia, in retina, 50f–51f, 52
- Microinfarction, 509, 509f
- Microorganisms, activation of innate immune cells, 389–390
- Microphthalmia, 112b
- Microsomal enzyme system, 342–343, 343b
- Microtubules, 174, 177f
- Microvascular occlusion, 509–510
- Midbrain  
lesions, 331  
reflex eye movement, 330–331, 332f
- Midget bipolar cells, 280–282
- Midget ganglion cells, 280–282  
microcircuitry, 294
- Mimecan, 205
- Miosis, 28
- Missense mutation, 137b
- Mitochondria, 164–169, 375f  
and apoptosis, signaling pathways in, 168b  
membrane organization in, 167f
- Mitochondrial disorders, 156, 490b, 490f
- Mitochondrial inheritance, 138, 156
- Mitochondrion inner membrane organizing system (MNOS), 164
- Mitogen activation of cells, signaling of, 164, 166b, 166f
- Mitosis, 130–131  
stages of, 131b
- Moesin/yurt, 255
- Molecular biology, 146
- Molecular genetics, 132–135, 150–156, 152t  
ophthalmology and, 150–156
- Molecular mimicry, 444
- Molecular typing, 450
- Monoamine oxidases, 363
- Monochromatism, 307
- Monoclonal antibodies (Mabs), 399
- Monocular rivalry, 317–318, 319f
- Monocular vision, 309–313
- Monocytes, 375f, 377  
migration of, 387
- Monosomy, 136.e1
- Moore's ulcer, 455–456
- 'Morning glory syndrome', 119b
- Morula, 103.e2
- Motion detection, 319–320, 320f, 324–325  
rods, 271
- Motion displacement, detection of minimum stimulus for, 279
- Motor root, of trigeminal nerve, 74
- Mould, 463t, 475
- 'Movement field', 332
- Mucins, 200, 201f  
deficiency of, 354  
ocular surface, 463–464, 463f
- Mucolytics, 355
- Mucormycosis, inflammatory disease, 497–498, 498f
- Mucosa-associated lymphoid tissue (MALT), 202, 416
- Mucosal immune system, 416
- Müller cells, 49–52, 50f–51f  
development of, 114–115  
glucose metabolism, 243  
glycogen stores, 190
- 'Müller's muscles', 30
- Multifactorial traits, continuous or discontinuous, 138–139
- Multifocal electroretinogram (ERG), 299, 300f
- Muscle fibres, of ciliary body, 30
- Muscular dystrophy, 189
- Mutation, 136
- Mycobacterium tuberculosis*, 494–495
- Mycophenolate mofetil, 364
- Mydriasis, 28, 216
- Myeloid-derived progenitor (MDP) cells, 378.e1f
- Myeloid mononuclear cells, 377–378
- Myeloid system, 377–380
- Myeloma, 507
- Myocillin, 227
- Myocytes  
eyelid, 129.e4  
migration, 129
- MyoD* gene expression, 129
- Myoid, 41–45
- Myopia, 215, 209.e1
- Myositis, orbital, 456
- Myotonic dystrophy, 137b, 155–156
- N**
- $\text{Na}^+/\text{Ca}^{2+}$  exchanger protein, 249–250, 259–261
- NADH, 189
- NADPH, 189, 209
- Naevi, 521–522, 522f
- $\text{Na}^+/\text{H}^+$  exchanger protein, 207–208, 208b
- $\text{Na}^+/\text{K}^+$ ATPase, 208–209  
in lens, 235
- Nanodiscs, 188.e1, 188.e2f
- Nanophthalmia, 112b
- Nasal cavity, 1
- Nasal mucosa, drug absorption in, 347–348
- Nasociliary nerve, 69–71
- Nasolacrimal duct, 92, 129.e4  
developmental anomalies of, 129.e6b
- Nasolacrimal groove, 129.e4
- Nasopharyngeal mucosa, drug absorption in, 347–348
- Natural killer (NK) cells, 375f, 381, 390–392  
membrane damage, 412
- Natural killer-T (NK-T) cells, 375f, 390–392
- N-CAM, 255
- Necrosis, 489
- Neoplasia, 518–538  
pathogenesis of, 519–521
- Neoplasms  
classification of, 519  
misdiagnosis, 537–538  
pathogenesis of, 519–521
- Neovascularization  
preretinal, 511  
of retina, 510
- Nervus intermedius, 77
- Nestin, 148–149
- Nettleship-Fells syndrome, 155
- Neural cells, photoreceptor responses, 305–306
- Neural crest, 104f–105f, 103.e3f  
cell migration and differentiation, 112, 114f  
fate of cells, 111  
mapping of, experimental methods of, 112.e1b
- Neural layer, 14f
- Neural plate, 103
- Neural progenitor cells, 148
- Neural tube, 103, 104f–105f  
malformations of, 112b
- Neural tumours, 526–533
- Neuroblastic layer, 108–110
- Neurocan, 215
- Neurocranium, 1
- Neurocristopathies, 129.e5b
- Neurofibroma, 526–529
- Neurofibromatosis type 1, 489b
- Neuroglia, retinal, 49–52
- Neurone, visual stimulus detection, 270–271
- Neurospheres, 148–149, 150f
- Neurotransmitter(s), 265  
corneal, 210  
retinal, 265t  
serotonin as, 363
- Neutrophilic granulocytes, 377
- Neutrophils, 376f, 377  
allergic disease, 448  
antibacterial agents, 383t  
bacterial killing, 467–469, 468b



- infiltration and activation of, 470f
- migration, 388f
- professional phagocytes, 389
- pyogenic infection, 494
- recruitment of, 464
- respiratory burst, 383, 385b, 385f
- New ophthalmic delivery systems (NODS), 351
- NF-1* gene, 520–521
- Night blindness, 258–259
  - choroideraemia, 153–154
  - congenital stationary, 150–151
  - in retinitis pigmentosa, 514
- Nitric oxide
  - host response to injury, 383, 385b, 385f
  - and retinal blood flow, 246
- Nitric oxide synthase (NOS), inhibition of, 360b
- N*-methyl D-aspartate (NMDA), 360b
- NOD-like receptors (NLRs), 464–467, 467b, 467f–468f
- NOD2* gene, 464–466, 467b
- Non-granulomatous inflammation, 500
- Non-steroidal anti-inflammatory drugs (NSAIDs), 361
- Nonsense mutation, 137b
- Norepinephrine
  - sympathetic system, 357, 357f
  - synthesis of, 358f
- Norma frontalis*, 3f
- Norma lateralis*, 3f
- Norrie's disease, 154, 154t
- Northern blotting, 142–143
- Notochord, 103.e2
- Nouin's technique, 317
- Nuclear factor- $\kappa$ B (NF- $\kappa$ B), 389
- Nuclear lesions, of facial nerve, 80b
- Nuclear pores, 164
- Nucleolus, 169
- Nucleotide substitution, 137b
- Nucleus, 166b, 169, 170f
  - intermediate filaments, 173–174
  - ligands, receptors for, in, 169
  - receptor mediated transport in, 166b, 169
- Nutritional deficiencies, 488
- O**
- Object positioning, 309–310
- Obligate intracellular, 463t
- Oblique muscle, of eye, 67t
- Occipitofrontalis, 81, 81f
- Ocular albinism, 155
- Ocular appendages, 77–92
- Ocular dominance, 317–318
- Ocular embryology, 103–111
- Ocular inserts, 350, 351b
- Ocular lubricants, 354–355
- Ocular muscles, eye movements, 326, 327b, 327f
- Ocular Response Analyzer® (ORA), 207
- Ocular surface, biochemical processes, 198–203
- Ocular surface disease, 501, 502f
  - progressive, 454–461
- Ocular toxicity, from systemic
  - administration of drugs, 368–369
- Oculocervical reflexes, 330
- Oculocutaneous albinism, 155
- Oculomotor cerebellar centre, 334–335
- Oculomotor nerve, 69–71
  - lesions of, 71b
  - origin of, 69, 73f
  - sensory endings in, 74
- Oculotoxic drugs, 369
- Oculovestibular reflexes, 329–330
- OFF bipolar cells, 292–293, 293f–294f, 306
- OFF response, 288–291
- Ointments, 350
  - ophthalmic, 354
- Oligodendroglia, 118–119
- Oligonucleotides, anti-sense/triple helix, 147
- 'OMICS' analysis, 145f
- ON bipolar cells, 292–293, 293f–294f, 306
- ON/OFF response, 288–291
- Onchocerciasis, 480–482
  - control of, 481–482
  - life cycle and parasite burden, 480
  - pathogenesis of, 480–481, 481f
- Oncogenes, 521
- Opacification, 212–213
- Ophthalmia
  - sympathetic, 139, 411f
  - microgranulomas, 411
  - systemic, granulomatous inflammation of, 502, 502f
- Ophthalmic artery, 7, 7f
  - aneurysm in, 99f
- Ophthalmic nerve, 75, 79f
- Ophthalmic surgery, materials used in, 501b, 501f
- Opponent colour theory, 306
- Opsin, 172f, 258, 275–276
  - and 11-cis retinal binding to, 259
  - and chromophore pocket, 258–259, 260f–261f
  - cone, 259, 262f, 304–305
- Opsonins, 389
- Optic canal, 1, 7, 10t
- Optic chiasma, 92–93, 93f–94f
- Optic cup, 104f–106f, 106–108
  - margin, 112–113
  - formation of, 112–113
- Optic disk, 39, 40f
  - development of, 117f, 118–119
- Optic fissure, 106–108
- Optic flow, 328–329, 328b, 328f
- Optic nerve, 7, 59–61, 60f
  - blood supply of, 60f, 61
- development of, 117f, 118–119
- glioma, 531–533
- intracanalicular portion of, 61, 62f
- intracranial portion of, 92, 93f
- intraocular portion of, 59–61, 60f
- lymphoma, 535–536
- malformations of head, 119b
- meningioma, 533
- orbital portion of, 60f, 61
- trauma response, 492
- Optic pit, 119b
- Optic radiations, 93f, 95, 96f
- Optic stalk, 104f–106f, 106, 117, 117f
  - development of, 117f
- Optic sulci, 103, 104f–105f
- Optic tracts, 93–94
  - lateral root of, 94
- Optic ventricle, 106
- Optic vesicle, 103, 104f–106f
  - malformations of, 112b
- Optical coherence tomography (OCT)-guided femtosecond laser surgery, 213
- Optical illusions, 312
  - Pulfrich phenomenon, 317, 318b, 318f
- Optogenetics, 148b
- Optoneurin gene, 227
- Ora serrata*, 30, 40
- Oral cavity, 1
- Orbicularis oculi muscle, 77–80, 81f
  - development of, 129.e4
- Orbit, 1
  - anatomy of, 1–102
  - blood vessels of, 68, 70f
    - anastomosis of, 70t
  - blow-out fractures in, 6b, 6f
  - contents of, 61–68
  - cysts, 537–538
  - extraconal space in, 63f
  - fibroadipose tissue of, 62–64, 62f
  - inflammatory disorders, 456–457, 458f
  - intraconal space in, 62–63, 63f
  - lipoma, 534
  - osteology of, 1–7, 4f–6f
  - osteosarcoma, 534
  - periosteum of. *see* Periorbita
  - walls of, 2–3, 5f
- Orbital aperture, 2
- Orbital cellulitis, 4b, 4f
- Orbital fissure
  - inferior, 5f–6f, 6–7
  - superior, 5–6, 5f–7f, 10t
- Orbital floor, 2, 5f
  - fractures in, 7.e1
- Orbital margin, 1, 3–5
- Orbital muscles, swelling, 456
- Orbital myositis, 456
- Orbital plate, 7–8
- Orbital roof, features of, 2
- Orbital septum, 82
- Orbital tubercle, lateral, 3

- Orbital wall, 2–3, 5f  
 lateral, 2–3, 5f  
 medial, 2, 5f
- Organ transplantation, solid, 451
- Organomercuric compounds, 354
- Orientation detectors, horizontal and vertical, 312
- Osteoprotegerin ligand, 378.e1b
- Oxidative stress, glucose-derived, 194
- $\alpha$ -Oxoaldehydes, 191
- Oxygen flux, 211
- Oxygen supply, reduced, 486
- Ozurdex®, 351
- P**
- p-21 activated kinases (PAKs), 173
- P cells, 291, 305–306
- p53 tumour suppressor protein, 147b
- P450 gene, in drug metabolism, 347
- P<sub>450</sub>-linked reductases, 193
- Pachymeninx, 9
- Pachytene, 131
- Paired-box genes, 110
- Palpebral fissure, 82
- Palpebral ligament, 81–82
- Palpebral part, of orbicularis oculi, 77–80
- Palpebral sulcus, 82
- Panretinal photocoagulation, 486–487
- Panum's area, 317
- Papillae lacrimales, 91–92
- Papilloedema, 62b
- Papilloma, 523
- Paramedian pontine reticular formation (PPRF), 329, 331, 332f
- Paranasal sinuses, 1, 4f, 7, 8f  
 development of, 129.e4
- Parasitic infection, 444–445
- Parasympathetic antagonists, 356–357
- Parasympathetic system  
 motor endplate of, 356f  
 ocular drugs, 355–357
- Parasympathomimetics, 355–356, 356b, 360b
- Parvocellular pathways, 321–322
- Patau syndrome (trisomy 13), 136.e1, 129.e6b
- Patellar fossa, 37, 37f
- Pathogen-associated molecular patterns (PAMPs), 371
- Pathogen-recognition receptors (PRRs), 379f, 390–392, 464
- Pathogens, 462, 463t
- Pathology, 486–538  
 ageing, 505–518  
 cell and tissue damage, 486–490  
 degeneration, 505–518  
 dystrophies, 505–518  
 healing and repair, 490–492  
 inflammation, 492–504  
 metabolic disease, 504–505  
 neoplasia, 518–538
- Pattern electroretinogram (PERG), 299
- Pax-6 gene, 107f, 111, 120–121
- Pax genes, 110
- Pax2 gene, 111
- Paxillin, 189
- PECAM-1, 387
- Pegaptanib sodium, 352–353
- Pemphigoid, 454–455, 501
- Pentose phosphate pathway, 190, 190f, 209  
 in cornea and lens, 190
- Peptidyl transferase, 133–134
- Perception, superior colliculus, 331–333, 334f
- Perforating/penetrating injuries, 486–487
- Perforin, 412  
 killing, 412f
- Periorbita, 62–64, 62f
- Peripheral nerve sheath tumours, malignant, 529
- Peripherin gene, 153
- Peroxiredoxin, 221
- Peroxisome proliferator-activated receptors (PPARs), 169
- Persistent hyperplastic primary vitreous, 532f
- Peter's anomaly, 120b, 127b  
 craniofacial abnormalities, 129.e5b  
 infantile glaucoma, 127b
- Phagocytes, professional, 389
- Phagocytosis  
 inflammatory response, 382  
 removal of damage tissue and microorganisms, 389
- Phagosomes, 375f, 492–493
- Phakomatous choristoma, 522
- Pharmacology  
 autonomic nervous system and, 355–358  
 drug-receptor interactions, 344–347  
 ocular, 338–369  
 pharmacodynamics, 344  
 pharmacokinetics, 338–344  
 tear film reconstitution, 354–355
- Pharyngeal arches, 129, 129.e1, 129.e2f, 129.e6b, 127.e1f  
 derivatives, 129.e3t  
 neural crest migration pathways, 129.e6
- Phosphatidylinositol  
 degradation of, 345–346  
 in lens, 236–237
- Phosphodiesterases, 345
- Phosphoinositide metabolism, 247
- Phospholipase A<sub>2</sub>, 197
- Phospholipase C, 345–346
- Phospholipids  
 flip-flop mechanism of, 345–346  
 structure of, 196b
- Photo-oxidation, rate of, 239
- Photochromatic interval, 303
- Photometer, 302
- Photoreceptors, 41–45, 44f, 161f, 246–254  
 bleached, 275–276  
 colour detection, 303–305  
 damage, 246f, 251  
 death signal for, 252, 252f  
 degeneration, 154b  
 electrical response, 287–288  
 hyperpolarization, 288  
 light energy, 273–274  
 lipids in, 247  
 metabolism, 246–247, 246f  
 plasma membrane, 163–164  
 potential difference, 288  
 proteins in, 249–250, 249t  
 renewal of, 244, 244b, 244f  
 and lipofuscin accumulation, 261–262  
 responses with neural cells, 305–306  
 resting potential, 298  
 retinal light stimulus detection, 291  
 shedding in, regulation of, 247, 248f  
 synaptic events with inner nuclear layer cells, 262–268, 265t  
 turnover, 246f  
 visual stimulus, 270–271
- Photosensitivity, retinal, 275
- Photosensitization, from systemic drug toxicity, 368–369
- Phototransduction, 263f, 261.e1b, 261.e1f  
 cascade, 261  
 electrical response initiation, 287–288  
 and phosphoinositide metabolism, 261
- Phthical eye, 507
- Physical agents, 486–487
- Physiological cup, 59–61
- Pia mater, 11f–12f, 13, 9.e1f
- 'Pie in the sky' defects, 101f
- Pierre Robin syndrome, 129.e5b
- Pigment epithelium-derived factor (PEDF), 255
- Pilocarpine, 223–225, 355, 356b  
 intraocular pressure control, 360b
- Pilomatrixoma, 523
- Pineal tumour, 531
- Pinguecula, 507
- Pituitary fossa, 9
- Pituitary gland, 9
- Pituitary stalk, 9
- Pizotifen, 363
- 'Place' cells, 310
- Plasma cells, 375f  
 inflammatory reactions of, 500  
 monoclonal proliferation, 507
- Plasma membrane, 161–164  
 lipid domains in, 161, 163f  
 proteins in, motion and tension of, 162b, 162f  
 tiny domains, 161
- Plasminogen activator, 214

- Plasminogen activator inhibitor 1 (PAI-1), 159, 185, 191–193
- Platelet-activating factor (PAF), 447
- Platelets, 376f, 386
- Plectin, 174
- Pleomorphic adenoma, 536–537, 536f
- Plica semilunaris, 85–86
- Pluripotential cells, 149f
- Point mutation, 137b
- Poly-A polymerase, 133–134
- Polyarteritis nodosa, 503
- Polyclonal antibodies, 399
- Polyclonal B-cell activation, 444
- Polymerase chain reaction (PCR), 143, 496b
- Polymorphisms  
DNA, 143  
genetic, 139
- Polymorphonuclear leucocytes (PMNs), 377, 453
- Polyplody, 136.e1
- Polyunsaturated fatty acids, in the retina, 245
- Pontine nucleus, 77
- Positional changes, 329–330, 331f
- Positron emission tomography (PET), 321
- Posterior pigment epithelium, 28, 29f
- Posterior polymorphous dystrophy, 518, 518f
- Posterior uveitis, microgranulomas, 411
- Potassium channels, in lens, 235
- Premalignancy, 519
- Preotic region, 129
- Presbyopia, 36b
- Preservatives, for drugs, 354
- Prestriate cortex, 269–270, 322–323
- Primary intraocular lymphoma, 535–536, 536f
- Primate brain, 335f
- Primitive streak, 103.e2
- Prochordal plate, 129
- Prodrug, 342
- Progressive outer retinal necrosis, 496–497
- Proliferative vitreal retinopathy, 48b
- Proline-arginine-rich and leucine-rich repeat (PRELP), 215
- Promoter, 133–135
- Prosencephalic vesicle, 103
- Prostaglandin(s), 220, 361–362, 362b
- Prostaglandin analogue, 360b
- Prostaglandin D<sub>2</sub>, 447
- Prostaglandin E<sub>2</sub>, 362b
- Prostaglandin F<sub>2 $\alpha$</sub> , 362b
- Prostaglandin I<sub>2</sub>, 362b
- Proteasome, 422.e1, 422.e1f
- Protein  
epitope mapping of, 430  
glycation, 190f, 191, 192f  
non-enzymatic, 191  
metabolism, retinal, 231f  
synthesis, 133b  
regulation of, 346–347
- Proteoglycans, 186, 186f, 186t, 188f  
fibril-regulating, 186  
organization of, 206b
- Proteomics, 143–145
- Proteosomes, 147.e1b
- Proto-oncogenes, 521
- Proton beam therapy, 487
- Protozoa, 463t
- Protozoal infection, inflammatory, 498–499
- Pseudoepitheliomatous hyperplasia, 538
- Pseudoexfoliation syndrome, 508
- Pseudomonas aeruginosa*, 462  
virulence factors, 473–474, 473f
- Pterygium, 507, 507f
- Pulfrich phenomenon, 317, 318b, 318f
- 'Pulley sleeve', 62–63
- 'Pulley suspensions', 62–63
- Pulvinar, 332–333
- Pupil, 26  
light reflexes, 286, 286b, 286f  
movements of, 28  
parasympathetic antagonists, 356  
size, 286
- Pupil zone, 26
- Pupillary margin, 26
- Pupillary membrane, 121–123
- Purine antagonists, 364
- Purkinje cells, 334–335
- Purkinje shift, 302–303, 302f
- Pursuit, 327–329
- Pyruvate, 239
- Q**
- Quadrantanopia, contralateral homonymous superior, 101f
- R**
- Radial streaks, of iris, 26
- Radiotherapy, 487
- Radixin, 255
- Ranibizumab, 352–353
- Ranitidine, 361
- Receptive fields, 288–291, 290b, 290f
- $\beta$ -receptors, 358
- Recombinant DNA, 142
- Recombinant DNA technology  
cloning, 142f  
Southern blotting, 143f  
X chromosome, 150–151
- Recombination rate, 140–141
- Recoverin, 261, 264f
- Rectus muscle, of orbit, 67t
- Red-green differentiation, 294
- Reflectance, 319
- Regulatory cells, mode of action of, 443f
- Release factor, 133–134
- Repeat expansions, 137b
- Resolving power of eye, 280, 282–283
- Resting potential, 298
- Restriction endonucleases, 142, 142f  
mapping, 146
- Restriction fragment length polymorphism (RFLP), 143, 146  
X chromosome, 150–151
- Reticular medial longitudinal fasciculus (RMLF), 331, 332f
- Retina, 38–55, 39f  
ageing changes in, 50b  
amacrine cells in, 43f, 47f, 49, 265–267  
association neurones in, 43f, 47f, 48–49  
astrocytes in, 49, 50f  
astrocytic hamartoma, 531, 532f  
biochemical processes, 242–258  
bipolar cells, 43f, 45–46, 47f, 263–265, 266f  
colour opponency, 306  
colour perception, 306  
microcircuitry, 265–266, 291, 293f, 295f  
blood flow in, 245–246  
blood-retinal barrier, 245  
autonomic control of, 245–246  
blood supply of, 40f, 52–55, 53f–54f  
central, 39  
circuitry, 291–296  
coloboma, 108b  
cones in, 44f, 45  
detachment of, 40b, 241, 242f  
dichromatic, 45  
differentiation of layers, 112–113  
dopamine neuromodulation, 267–268  
dysplasia, 129.e6b  
electrophysiology, 287  
ganglion cells in, 43f, 46–48, 47f, 267f  
glycogen stores, 190  
horizontal cells in, 43f, 47f, 48–49, 266–267  
feedback, 292f, 294–295  
inner neurosensory, 38  
inner nuclear layer of, 114–115, 115f  
photoreceptor synaptic events, 262–268, 265t  
interphotoreceptor matrix, 253–254  
retinal adhesion for, 253–254  
light sensing cones, 307f  
lipids in, 245  
lymphoma, 535–536, 536f  
metabolic function, 242  
microcircuitry, 291, 296  
microglia in, 50f–51f, 52  
morphogenesis of, 114–115, 115f  
Müller cells in, 49–52, 50f–51f  
neural, 108–110  
axes in, 113–114, 114f

- derived from neuroepithelium, 112–118
    - development of, 117
  - neuroglia in, 49–52
  - neurosensory, 41, 43f
  - neurotransmitters in, 265t
  - outer nuclear layer of, 114–115, 115f
  - peripheral, 39
    - development of, 117
  - photochemical reactions in, 258–259
  - photoreceptors in, 41–45, 44f
  - photosensitivity, 250–251, 251f, 275
  - posterior pole of, 39
  - protein metabolism, 231f, 243–245
  - regions of, 38–40, 40f
  - rhodopsin content, 275
  - rod cells in, 41–45, 44f
  - shedding in, 247
  - transient layer of Chievitz, 114, 115f–116f
  - trauma response, 492
  - trichromatic, 45
  - vasculature, development of, 117, 117f
- 11-cis Retinal, conversion of, 257, 257f, 259, 260f–261f
- Retinal artery, central, 40f, 52–55, 53f–54f
  - development of, 117
  - occlusion, 55b
- Retinal capillaries, 53
  - networks of, 54f, 55b
- Retinal cells
  - differentiation of, 148f
  - electrophysiology, 288–291
- Retinal connections, 291–296, 293f, 299.e1f
- Retinal degeneration
  - microcystoid, 528f
  - routes for intervention for, 151f
- Retinal degeneration show (RDS) protein, 153, 249–250, 250f
- Retinal disk, 104f–105f, 106, 112–113
- Retinal disorders, gene loci, 153f
- Retinal dystrophies, 514–515
- Retinal ganglion cells
  - axons from, 118–119
  - colour-opponent mechanism, 306
  - embryology of, 118–119
  - M cells, 305–306
  - organization, 294–295
  - P cells, 305–306
  - responses, 306
  - types, 296, 297f
  - visual acuity, 285
- Retinal neuroglia, 49–52
- Retinal pigment epithelium, 40–41, 42f, 160–161, 161f
  - ageing changes in, 41b
  - bidirectional transport in, 257–258
  - biochemical processes, 254–258
  - and blood-retinal barrier, 255
  - cell size, shape and structure of, 41, 42f
  - development of, 116f, 117–118
  - embryology, 108–110
  - function of, 256f, 256t
  - lipofuscin accumulation, 261–262
  - lysosomes of, 262
  - in macular degeneration, 513–514
  - melanin, 108–110, 253, 256–258
  - phagosomal system of, 256–257
  - photoreceptor function and, 256–257
  - pluripotent cell function, 254–256
  - resting potential, 298
  - and tight junctions, 257–258
  - transport function, 258
  - turnover, 255
- Retinal rivalry, 317–318
- Retinal slip prevention, 335
- Retinitis
  - acquired immunodeficiency syndrome, 497
  - AIDS, 403.e2
  - CMV, 459
    - treatment of, 352.e1b
  - cytomegalovirus, 472–473, 497, 497f
  - viral, 472–473
- Retinitis pigmentosa, 151–153, 251, 514–515, 515f
  - albescens, 153
  - autosomal dominant, 153
  - autosomal recessive, 153
  - X-linked, 151
- Retinoblastoma, 154–155, 529–531
  - differential diagnosis of, 531, 532f
  - histology of, 529–531, 530f
  - trilateral, 531
- Retinoblastoma (*Rb*) gene, 154–155, 521
- Retinoblastoma predisposition gene, 154–155
- Retinoic acid, 259
  - topical, and wound healing, 215
- Retinoic acid receptors, 129.e6
- Retinoid
  - conjunctival epithelium, 202
  - shuttling mechanism, 257
- Retinol, isomerization of, 172f, 248, 248b, 248f, 257f, 258–259
- Retinopathy
  - from chloroquine, 368
  - diabetic, 504
  - myotonic dystrophy, 155–156
  - of prematurity, 510b
  - proliferative vitreal, 48b
- Retinopathy of prematurity, 118b, 118f
- Retinoschisin, 264–265, 266f
- Retisert®, 351
- Retrolental fibroplasia. *see* Retinopathy of prematurity
- Reversion-inducing cysteine-rich protein with Kazal motifs (RECK), 383
- Rhabdomyoma/rhabdomyosarcoma, 533, 534f
- Rheumatoid arthritis, 455–456
  - systemic amyloid deposition, 507
- Rheumatoid eye disease, 501
- Rhodopsin, 41–45, 249, 249f, 258–259, 261, 261.e1, 261.e1f
  - activation of, with light, 258, 260f–261f
  - acylation of, 246, 247f
  - arrestin interaction, 430f
  - bleached, 276
  - electrical response, 287
  - glycosylation of, 246, 247f
  - insertion of, into disc plasma membrane, 244b, 246
  - molecule, 153
  - in photoreceptor disc, 172f
  - regeneration, 275
  - retinal content, 275
  - synthesis of, 248b, 248f
- Ribbon synapses, 264–265
- Ribosomal RNA (rRNA), 138
- Ribozymes, 147
- Ricco's law, 278
- Rieger's anomaly, 120b, 127b, 129.e5b
- River blindness, 480–482
  - see also* Onchocerciasis
- RNA, non-coding, in gene expression, 135
- RNA-binding proteins, in gene expression, 135
- RNA polymerase, 133–135
- Robertsonian translocation, 136
- Rod(s), 41–45, 44f
  - bipolar, 46
  - horizontal cell feedback, 292f, 294–295
  - light photon absorption, 275
  - microcircuitry, 293–294
  - motion detection, 271
  - outer segment tip phagocytosis, 262
  - spherules, 44f, 45
  - stimulation, 278
- Rod monochromatism, 307
- Rosenthal fibres, 533, 533f
- Rough endoplasmic reticulum (RER), 164
- RP3 gene defect, 153–154
- RPE65 enzyme, 252
- Ru plaque, 487
- Rubin vase, 308–309, 309b, 309f
- S**
- Saccades, 327, 330b, 330f
  - initiation, 333
  - voluntary, 333
- Sarcoidosis, 456–457
- Schiff base products, 191, 192f
- Schlemm's canal, 24, 25f
  - aqueous humour drainage, 227–228
  - development of, 127, 128f
- Schrodinger staircase, 308–309, 309b, 309f
- Schwalbe's line, 120b

- Schwannoma, 526–529
- Sclera, 20–21, 22f  
   ageing changes in, 22b  
   biochemical processes, 215–216  
   collagens, 182, 205  
   development of, 119  
   fibroblast in, 215  
   fluid transport, 186f, 203–204, 215–216  
   inflammatory disorders, 456–457, 458f  
   matrix, 215  
   nanophthalmia, 216  
   stroma of, 22f  
   trauma response, 492
- Scleral canal, 59–61
- Scleral spur, 21–22  
   development of, 127
- Scleral sulcus, 21–22
- Scleritis, 456  
   immunopathology of, 457f
- Sebaceous adenomas, 523
- Sebaceous gland carcinoma, 525, 525f
- Second messenger systems, 159, 159f, 177
- Second messengers, drug-receptor interactions, 345, 345b, 345f
- Seeing, frequency, 274
- Segmentation genes, 110
- Selectins, ligand interactions, 386–387
- Selector genes, 110
- Selenite, cataract formation, 239–240
- Self-organization, of eye, 157, 158f
- Sella turcica, 10t
- Semicircular canals, 329
- Sensory root, of trigeminal nerve, 74
- Septins, 177, 178f
- Serotonin, 363  
   receptors, 363
- Shape  
   detection, 319  
   discrimination, 273  
   processing, 273, 273f
- Sheddases, 182
- Signal amplification, 259–261, 263f
- Signalling mechanisms, intracellular, 177–178
- Signalling molecules, 157
- Signalling networks, 159, 159.e1, 159.e1f, 159.e2b
- Signalling pathways  
   apoptosis, 168b  
   endoplasmic reticulum, 164, 166b  
   Golgi apparatus, 164, 166b
- Single gene defects, 488–489
- Sinus venosus sclerae. *see* Schlemm's canal
- Sirtuins, 190
- Six3 gene, 111
- Sjögren syndrome, 354, 456–457, 500–501  
   malignant transformation, 519
- Skeletal metastases, 507
- SKILL test (Smith-Kettlewell Institute Low Luminance test), 279
- Skull  
   arrangement of, 1  
   chondrocranium, 129.e1  
   development of, 129.e1  
   features of, 1  
   osteology of, 1–13, 3f  
   viscerocranium, 129.e1
- Slow acetylators, 346–347
- Slow-releasing substance of anaphylaxis (SRS-A), 361
- Smooth endoplasmic reticulum (SER), 164
- Snellen's test type, 280–282
- Sodium channels, cell depolarization, 287–288
- Sodium coupled monocarboxylate transporters, 242–243
- Sodium cromoglycate, 361
- Sodium/potassium ATPase pump, 359.e2b
- Solitary fibrous tumour, 534
- Solutions, ophthalmic, 354
- Somitomes, 112, 114f
- Sonic hedgehog, 111
- Sorbitol, 191  
   pathway, 191f, 235
- Southern blotting, 142–143, 143f, 146
- SPARC (sialo-protein associated with rods and cones), 185, 234, 253–254
- Spatial constancy, 310, 322
- Spatial perception, 309
- Spatial resolution, 271
- Spectral mixing curves, 303, 304b, 304f
- Spectral reflectance densitometry, 304
- Spectral sensitivity curves, 302–303
- Spectrophotometers, 302
- Sphenoidal sinus, 4f, 8f, 7.e1
- Sphincter pupillae muscle, 26, 27f, 28, 126, 216
- Sphingomyelin, lens fibre cell content, 233, 236, 237f
- Spina recti lateralis, 2–3
- Spinal nucleus, 77
- Spinocerebellar ataxia, 137b
- Spirochaetes, 494–495
- Spleen, 415, 415f
- Splice site mutation, 137b
- Spliceosomes, 135
- Spores, 475
- Squamous cell carcinoma, 523–525, 524f
- Staphylococcal enterotoxins (SE), 432
- Staphylococcus aureus*, 474
- Stargardt's disease, 515, 516f
- Stem cell(s), 412–413  
   bone marrow, 438
- Stereoacuity, 316–317, 317f
- Stereopsis, 312–317, 324–325  
   image disparity, 317  
   measurement, 314–317
- Steroids, 363–364  
   for idiopathic orbital inflammation, 538  
   as oculotoxic drug, 369  
   in protein synthesis regulation, 346  
   in trabecular meshwork, 227
- Stevens-Johnson syndrome, 455
- Streptococcus pneumoniae*, 474
- Striate cortex (area V1), 322–323, 323f  
   processing, 323
- Stroma  
   ablation of, 213  
   atrophy, 518  
   dystrophies, 516–517
- Stromelysin, 214
- Structural proteomics, 145
- Structure from motion (SFM) information, 310
- Sturge-Weber syndrome, haemangiomas, 521
- Subarachnoid cisterns, 12, 9.e1f
- Subarachnoid space, 9, 9.e1f
- Subbasal plexus, 20
- Subdural haematomas, 13b
- Subepithelial plexus, 20
- Sublethal cell injury, 490
- Subretinal space, 38, 108–110  
   lymphoma, 535–536
- Substantia nigra, 333
- Substantia propria, 16–18, 18f
- Subtarsal sulcus, 85
- Sudoriferous cysts, 537
- Sugars, antigen presentation, 432
- Sulcus chiasmatica, 9, 10t
- Summation, 288–291  
   binocular, 279  
   spatial, 278  
   temporal, 278–279, 279.e2f
- Sunflower cataracts, 489b
- Superantigens, 431–432, 444
- Superior colliculus, 94  
   eye movement control/perception, 331–333
- Superoxide anions, 193  
   host response to injury, 383
- Superoxide dismutase, 193–194, 194b, 194f, 252–253
- Suprachoroid, 58
- Supranuclear lesions, of facial nerve, 80b
- Supratentorial compartment, 12.e1
- Surface ectoderm, 103–106, 119–120
- Surface epithelium, benign tumours of, 523
- Sutures, 1
- Sweat gland adenoma, 523
- Sweat gland cysts, 537
- Switch genes, 110
- Symblepharon, 501
- Sympathetic ophthalmia, 502, 502f
- Sympathetic system, 357–358, 357f
- Sympathomimetic drug receptor, profile/action of, 359.e2t
- Synapse, 172.e1, 172.e1f

Synaptic potentials, 288–291

Synaptic ribbon, 45

Syndecans, 186–188

Synophthalmia, 112b

Systemic amyloid deposition, 507

Systemic lupus erythematosus, 444, 503–504

Systems biology, 159

## T

T cell(s), 380

activation, 427–437

antigen response, 395–396

clonal expansion, 395–396

cytotoxicity, 412

deletion, 444

development and maturation, 413–414

differentiation, 382f, 421f

effector response, 396

maturation, 413–414

memory, 420

stages of activation, 365f

suppressive, 421

tolerance, 443

trafficking, 412

$\gamma\delta$ T cell(s), 390–392, 431

T cell receptor (TCR), 380

antigen binding, 427–432, 429f

chains, 429

gene expression, 430

immunoglobulin gene segment data, 428.e1

regions, 429f

T helper (Th) cells, 380, 447–448

response in parasitic infections, 449f

T regulatory cells, 420–421

active suppression by specific

lymphocytes, 443

Tacrolimus, 364b, 437

Takayasu's disease, 503

Talin, 189

Tapetum, 56b, 56f

Tarsal plates, 82

TATA box, 134–135, 439

Taurine, 243–244

Taxol, 174

Tear(s), 198

antimicrobial compounds, 463

aqueous component of, 199–200

artificial, 354–355

complement, 463

in drug administration, 348

IgA, 199–200, 380–381, 453–454, 463

IgG, 463

lipid, 453

mucins, 199–200, 201f, 348

deficiency, 354

ocular infection barriers, 453, 463

pH, 348

protein concentration of, 200f

secretion

by lacrimal gland, 200, 202.e1, 202.e1f

psychoneuroendocrine control of, 201, 201f, 202.e1

Tear film, 89, 198–201, 198f, 202.e1

break-up time, 198

characteristics of, 196b, 198–199

composition of, 199t

evaporation, 198

lipids, and lung surfactant, 198–199, 199f

precorneal, 348

reconstitution of, 354–355

viscosity, 200

Tear meniscus height (TMH), 198

Tear-specific prealbumin, 199–200

Tear substitutes, 354–355

Tectum, 94

Tegmen tympani, 10t

Telodendria, 45

Temperature, extremes of, 486

Temporal arteritis, 503, 503f

Tenascin, 183, 184f, 234, 244–245

Tenon's capsule, 62

Tentorium cerebelli, 12, 12.e1

Teratogenic agents, facial defects, 129.e6

Teratoma, 522

Tertiary lymphoid organs (TLOs), 416, 417f

Texture analysis, 319–320, 320f

Texture perception, 324–325

Thalamus, 'place' cells, 310

Thiomersal, 354

Three receptors, molecular evidence for, 304–305

Thrombosis, in cavernous sinus, 13b

Thrombospondins, 184f, 185, 214–215

Thromboxanes, 361–362, 362b

Thymus

bi-lobed, 413f

regulates T-cell development, 413–414

Thyroid eye disease, 504

'Tic douloureux', 77b

Tight junctions, 172.e1, 172.e1f

Timolol, 220, 360b

Tissue damage

agents and conditions causing, 486–489

cellular mechanisms of, 410–412

Tissue glycation, 189–193

Tissue inhibitor of matrix

metalloproteinases (TIMPs), 185, 254

host response to injury, 383

Tissue plasminogen activator (tPA), in

trabecular meshwork cells, 226–227

Tissue transplantation, 450–451

Tolerance induction

mechanisms of, 442–443

sites of, 441–442

Toll-like receptors, 389, 390t, 391f, 464, 466f

*Toxocara* (toxocariasis), 459, 480

*Toxocara canis*, 480, 499

*Toxocara cati*, 480

*Toxoplasma*, 372, 459

*Toxoplasma gondii*, 462, 478–479, 498, 499f

Toxoplasmosis, 478–480

host response to, 479

life cycle of, 479f

ocular, 480

Trabeculae, 10

Trabecular meshwork, 24, 25f

aqueous outflow, 226

detoxifying enzyme systems in, 227

metabolism of, 226–227

prostaglandin synthesis by, 227

Trabecular meshwork inducible

glucocorticoid response (TIGR) protein, 227

Trachoma, 202, 454, 482–483, 498b

in Australia, 483

clinical features of, 484f

Tracking, 310, 327

TRANCE, 403.e1

Trans-acting nuclear factors, 439

Transcellular pores, formation of, 226

Transcription, 133–134, 134f

accessibility for, 135

Transcriptome, 145

Transcriptomics, 143–145, 159

Transcytosis, 226

Transducin, 250, 264f

Transduction, 147

in drug-receptor interactions, 344

Transfection, 147

Transfer RNA (tRNA), 133–134

mitochondrial inheritance, 138

Transforming growth factor- $\beta$  (TGF- $\beta$ ), 159, 191, 227, 403.e2

Transforming growth factor- $\beta$ -induced (*BIGH1*) gene, associated corneal dystrophies, 517b

Translation, 133–134, 134f

Translocation, 136

Transmembrane collagen XVII, 182

Transmembrane proteoglycans, 186, 188f

Trauma

blunt, 537–538

haematic cyst, 537–538

mechanical, 486–487

Treacher Collins syndrome, 129.e5b

Treg activity, failure of, 444

Trichromatism, anomalous, 308

Trigeminal ganglion, 74

Trigeminal impression, 10t

Trigeminal nerve, 20, 74–77, 78f

development of, 129.e4

sensory nuclei of, 77

Trigeminal neuralgia, 77b



- Triple helix
    - collagens, 178–180, 179b, 179f, 181f
    - oligonucleotides, 147
  - Triplet repeats, 137b
    - myotonic dystrophy, 155–156
  - Trisomies, autosomal, 136.e1, 136.e1f
  - Trisomy 13, 136.e1, 129.e6b
  - Trisomy 18, 136.e1
  - Trisomy 21, 136.e1, 129.e6b, 136.e1f
  - Trochlear fossa, 2
  - Trochlear nerve, 71–74
    - lesions of, 71b
    - origin of, 71, 75f
  - Trophoblast, 103.e2
  - Troxler phenomenon, 286–287
  - Tryptophan, 238–239
  - Tuber cinereum, 9, 92–93
  - Tuberculoma, 495f
  - Tuberculum sellae, 9
  - Tumour(s)
    - benign, 519
    - choristomas, 522
    - connective tissue, 534
    - cytogenetics, 529b
    - epithelial
      - benign, 523
      - malignant, 523–525
    - hamartomas, 521–522
    - histological classification of, 520t
    - lacrimal gland, 536–537
    - lymphoid, 534–536, 535f
    - metastatic, 537
    - muscle-derived, 533
    - neural, 526–533
    - spread and metastases, 521
    - teratoma, 522
    - vascular, 533–534
  - Tumour necrosis factor (TNF), 214,
    - 401–402, 403.e1
    - superfamily, 403.e4b–403.e5b, 403.e4f–403.e5f
  - Tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), 147b,
    - 365–366, 367f, 387–388
    - acute phase response, 394
    - viral infections, 468b
  - Tumour suppressor genes, 521
    - p53, 147b
    - retinoblastoma gene, 154–155
  - TUNEL staining, 147
  - Tunica vasculosa lentis, 121–123, 123f
    - persistent, 124b
  - Tunics, 13, 14f
  - 'Turkish saddle', 10t
  - Turner syndrome, 136.e1
  - 'Two-hit hypothesis', 154–155
  - Tyrosinase, albinism, 155
- U**
- Ubiquitin, 164.e1, 147.e1f, 164.e2f, 147.e1b
    - conjugation in lens, 236
  - Ubiquitin-proteasome system, 227
  - Ubiquitinylation, 164
  - Ultraviolet light, cataract formation, 238–239
  - Unfolded protein response (UPR), 164
  - Uveal effusion syndrome, 215–216
  - Uveal melanoma, 525–526, 527f
  - Uveal meshwork, 24, 25f
  - Uveal tract, 14f, 26
    - biochemical processes, 216–222
    - development of, 124–127
    - inflammation of, 502
    - systemic drug toxicity, 368
  - Uveitis
    - acute anterior, 459
    - intraocular, 459.e1
    - lens-induced, 501–502, 502f
    - posterior, 459
  - Uveoretinitis, experimental autoimmune, 459
- V**
- Variable number of tandem repeats (VNTR), 143
  - Varicella zoster virus, in acute retinal necrosis, 496
  - Vasa hyaloidea propria, 121
  - Vascular cell adhesion molecule (VCAM), 387
  - Vascular endothelial growth factor (VEGF), 353b
  - Vascular endothelial growth factor A (VEGF A), 353b, 392
  - Vascular endothelial growth factor receptor (VEGFR), 353b
  - Vascular endothelium
    - inflammatory response, 386
    - leucocyte adhesion, 386
  - Vasculitis, 503
  - Vaso-occlusive disease, 508
  - Vasodilator-stimulated phosphoprotein (VASP), 189
  - Vectors
    - non-viral, 148b
    - viral, 148b
  - Vernier acuity, 280, 282
  - Versican, 215
  - Vertical gaze centre, 331, 332f
  - Vestibular apparatus, 329
  - Vestibulo-ocular reflex, 329, 335
  - Viewing, binocular, 287
  - Vimentin, 174
  - Viral infections, 471–473
    - herpes stromal keratitis, 471–472
      - angiogenesis and lymphangiogenesis, 471
      - latency of, 471–472
      - primary infection, 471
      - retinitis, 472–473
  - Viral vectors, 148b
  - Virulence
    - microbial, 462
    - of *Pseudomonas aeruginosa*, 473–474
  - Viruses, 463t, 495–497
    - inflammation and, 488, 495–497
  - Viscerocranium, 1
    - development of, 129.e1
  - Vision, 269–271
    - binocular, 309–313
    - depth perception, 273, 312, 314f
    - form discrimination, 273
    - limits, 271
    - measuring by eye, 311
    - minimal stimulus, 274
    - monocular, 309–313
    - physiology of, 269–337
    - shape discrimination, 273
  - Visual acuity, 279–280, 279.e3f
    - assessment, 280b, 281f
    - best corrected, 285–287
    - binocular summation, 279
    - contrast sensitivity, 283–284
    - limits of and limitations, 280–283, 283b, 283f
    - luminance, 280
    - pupil size, 286
    - retinal ganglion cells, 285
  - Visual association areas, secondary, 95, 97f
  - Visual cortex
    - hemifield maps, 323f
    - line orientation, 312
    - object selective regions, 326f
    - organization, 323–326
    - primary, 95, 97f
      - cytoarchitecture of, 97f
    - smooth pursuit eye movements tracking, 333–334
    - ventral, 270f
    - visual space mapping, 324, 324f–325f
  - Visual cortical cells, 269–270
  - Visual electrophysiology, clinical, 296–301, 297f
  - Visual evoked potential (VEP), 299–301, 301f
  - Visual field, 270–271
    - driving licence requirement, 316f
  - Visual illusions, 309b, 309f
  - Visual pathway
    - anatomy of, 92–102, 93f
    - blood supply of, 98f, 102
    - disturbances on, 97
    - retinotopic organization of, 97
  - Visual perception, 308–320
    - probability theory, 287
  - Visual process, 269–270
  - Visual response, chemistry of, 258–268
  - Visual stimulus/stimuli
    - binocular summation, 279
    - differential, 282
    - minimal, 274
    - size, 277–278

Visual system physiology, 269–337  
 division of labour, 321–326, 321f  
 electrophysiology, 287–302  
 imaging studies, 321, 322f  
 ocular movement, 326–336  
 Visual threshold, 273–274  
 Vitamin A, 258–259  
 conjunctival epithelium, 202  
 Vitamin B<sub>6</sub>, 193, 197  
 Vitamin E  
 as free radical, 264b, 264f  
 free radical scavenger activity, 198  
 and light damage, 239, 239f  
 and photoreceptor damage,  
 252–253  
 regeneration of, 264  
 Vitelliform dystrophy, 515, 516f  
 Vitreal collagen, production of, 31–32  
 Vitreal hyaluronic acid, production of,  
 31–32  
 Vitreoretinopathy, familial exudative,  
 154  
 Vitreous, 37–38, 37f  
 base, 123, 125f  
 biochemical processes, 240–242  
 and glucose transporters (GLUTs),  
 243  
 glycosaminoglycans, 186  
 hyalocytes, 241  
 and lens clarity, 242, 243f  
 matrix of, 240–241  
 physiochemical properties of,  
 241–242  
 collagens, 182, 240–241, 241f  
 type IX, 240–241  
 development of, 121–124

gel physiochemical properties of  
 bulk flow, retardation of, 241–242  
 deformation of globe, protection  
 from, 241  
 diffusion of small molecules,  
 retardation of, 241–242  
 retina, protection of, 241  
 hyalocytes in, 38, 39f  
 lymphoma, 535–536  
 malformations of, 124b  
 persistent hyperplastic primary, 124b  
 posterior detachment of, 38b  
 primary, 121  
 pyogenic infection, 494  
 secondary, 123  
 tertiary, 123  
 VLA-4, 435  
 Vogt-Koyanagi-Harada syndrome, 139

## W

Waldenström's macroglobulinaemia, 507  
 Water  
 and rhodopsin conformation, 172f, 259  
 transport  
 and AQP0 gene, 233  
 in lens, 235  
 Wavelength  
 contrast sensitivity, 284–285  
 discrimination, 292, 322–323  
 WD repeat domain (WDR36) gene, 227  
 Wegener's granulomatosis, 503  
 Wilson's disease, 489b  
 Wnt signaling, 251–252, 178.e1, 178.e1f  
 Wolfram (WFS1) gene, 238  
*Wuchereria* spp., 499

## X

X chromosome, 150–151  
 Xanthine, 193  
 Xanthine oxidase, 221  
 Xanthophyll macular pigments, 253, 254f  
 Xenograft rejection, 451  
 X-linked disorders, 137–138  
 mapping of, 150–151  
 ocular disease, 152t  
 retinitis pigmentosa, 151

## Y

Yeast, 463t, 475  
 Yolk sac, 103.e2  
 Young-Helmholtz trichromatic theory,  
 306

## Z

ZAP-70, 436–437  
 Zeaxanthin, 253, 254f  
 Zidovudine (AZT), 352.e1b  
 Zonular apparatus. *see* Lens zonules  
 Zonule(s)  
 collagens, 182  
 production of, 31–32  
 relaxation of, 217–218, 218f  
 Zonules of Zinn, 35  
 Zygomatic foramen, 2  
 Zygomatic nerve, 75  
 Zygote, 131  
 Zygotic genes, 110